

**Associate Professor Alexander C.J. van Akkooi**

**MSc, MD, PhD, FRACS**

### Personal Information

Melanoma Institute Australia  
40 Rocklands Road  
Wollstonecraft, NSW 2065, Australia  
Phone (W): +61 (0)2 9911 7200  
E: [alexander.vanakkooi@melanoma.org.au](mailto:alexander.vanakkooi@melanoma.org.au)



### Short Profile

Assoc. Prof. Dr. Alexander C.J. van Akkooi, MD, PhD, FRACS was born in Bridgeport, Connecticut, USA. He has both American and Dutch nationalities.

He studied medicine at the Erasmus University Medical Center, Rotterdam, the Netherlands, where he gained his MD title in 2008. During his surgical specialty training (2009-2014), he was awarded his PhD cum laude in 2011 on the thesis: "Sentinel Node Tumor Load Assessment in Melanoma: Dilemmas and Clinical Management".

From 2015 – 2021 he was a staff consultant surgical oncologist at the Netherlands Cancer Institute – Antoni van Leeuwenhoek (NKI) in Amsterdam, the Netherlands, where he chaired the Melanoma and Skin Cancer Centre. He is the immediate past-Chairman of the EORTC (European Organization for Research and Treatment of Cancer) Melanoma Group.

He is a Fellow to the Royal Australasian College of Surgeons (FRACS) within the Specialty of General Surgery within a defined scope of practice of Cutaneous Oncology.

He has served on multiple international committees, such as ASCO and ESMO. Prof. Dr. van Akkooi has published over 250 peer reviewed papers (H index 43) in many high impact journals (i.e. New England Journal of Medicine, Lancet, Lancet Oncol, Cell, Nature Med) and has presented at numerous domestic and international meetings. He joined the Melanoma Institute Australia (MIA) in 2022 as Associate Professor of Melanoma Surgical Oncology.

He is a clinical academic and his research work focuses on staging and treatment of melanoma, sentinel lymph node biopsy (SLNB), locoregional therapies, adjuvant and neo-adjuvant strategies and safe de-escalation of surgery. He is also a Merkel Cell Carcinoma (MCC) expert.

### Medical Education, Qualifications and Fellowships

- |      |                                                                                                                                                                                          |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2024 | Fellow of the Royal Australasian College of Surgeons ( <b>FRACS</b> ) in relation to the Specialty of General Surgery with a defined scope of practice in Cutaneous Oncology (11-1-2024) |
| 2015 | Board Certified Surgeon & Surgical Oncologist in the Netherlands (1-1-2015)                                                                                                              |

- 2014 Senior Resident General Surgery & Surgical Oncology in an accredited training program. Erasmus Medical Center – Erasmus MC Cancer Institute, Rotterdam, the Netherlands
- 2013 Senior Resident General Surgery & Surgical Oncology in an accredited training program. Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, the Netherlands
- 2009 – 2012 Resident General Surgery in an accredited training program. Maasstad Ziekenhuis – Rotterdam & Burn Center, Rotterdam, the Netherlands
- 2005 – 2011 Philosophy Doctorate (PhD) candidate at Erasmus University Medical Center – Daniel den Hoed Cancer Center, Rotterdam, the Netherlands  
Achieved title of Doctor of Philosophy (**PhD**) on January 19<sup>th</sup> 2011, *cum laude*
- Thesis: Sentinel Node Tumor Load Assessment in Melanoma: *Dilemmas and Clinical Management*
- Primary Supervisor: Prof. Alexander (Lex) M.M. Eggermont, MD, PhD. Professor of Surgical Oncology and head of department, Erasmus University Medical Center – Daniel den Hoed Cancer Center
- Co-supervisor: Christiane A. Voit, MD, PhD. Charité, Humboldt University of Berlin, Berlin, Germany
- 2006 – 2008 Internships at Erasmus University Medical Center, Rotterdam, the Netherlands  
Awarded the title of Medical Doctor (MD) on the 22<sup>nd</sup> of August, 2008
- 1999 – 2005 Studied Medicine at Erasmus University Rotterdam (EUR) – Erasmus University Medical Center, Rotterdam, the Netherlands  
Awarded Master of Science (MSc [Med]) on the 24<sup>th</sup> of March, 2005
- 1993 – 1999 Gymnasium- $\beta$  Baccalaureate, Erasmiaans Gymnasium, Rotterdam, the Netherlands

### Medical Employment

- 2022 – Present Faculty Member, Melanoma Institute Australia, Wollstonecraft, Sydney, NSW, Australia
- 2022 – Present Associate Professor, the University of Sydney, Faculty of Medicine and Health, Camperdown, Sydney, NSW, Australia
- 2022 – Present Clinical Academic, Royal Prince Alfred Hospital, Department of Melanoma and Surgical Oncology, Camperdown, Sydney, NSW, Australia
- 2015 – 2021 Consultant / Staff Specialist, Department of Melanoma and Soft Tissue Sarcoma, Division of Surgical Oncology, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, the Netherlands

- 2014 Senior Resident General Surgery & Surgical Oncology in an accredited training program. Erasmus Medical Center – Erasmus MC Cancer Institute, Rotterdam, the Netherlands
- 2013 Senior Resident General Surgery & Surgical Oncology in an accredited training program. Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, the Netherlands
- 2009 – 2012 Resident General Surgery in an accredited training program. Maastad Ziekenhuis – Rotterdam & Burn Center, Rotterdam, the Netherlands
- 2005 – 2011 PhD Candidate at Erasmus University Medical Center – Daniel den Hoed Cancer Center, Rotterdam, the Netherlands

### Research Overview

His research work focuses on, but is not limited to, the staging and multidisciplinary treatment of early stage (I-III) melanoma and non-melanoma skin cancer (NMSC). This includes the use of sentinel lymph node biopsy (SLNB), locoregional therapies, the role of lymph nodes dissections, metastasectomy surgery, adjuvant and neo-adjuvant strategies and safe de-escalation of surgery. He is also a Merkel Cell Carcinoma (MCC) expert.

### Grant Funding History

Start	End	Fund	Project	Role	Amount
2024	2024	Skyline Dx - Unrestricted Educational Grant	Meta-analysis of Clinical Prognostic & Gene Expression Profiles (CP-GEP)	PI	\$ 10.000,- AUD
2020	2023	Amgen - Unrestricted Educational Grant	NIVEC trial	Co-PI	€ 419.556,00
2020	2021	Merck Serono – Unrestricted Educational Grant	Merkel Cell Carcinoma (MCC)	CI	€ 23.200,-
2019	2020	Merck Serono – Unrestricted Educational Grant	Merkel Cell Carcinoma (MCC)	CI	€ 39.500,-
2018	2021	EORTC Melanoma Group - Unrestricted Educational Grant	Translational Research Project for In-Transit Metastases (ITM)	PI	€ 50.000,-
2017	2019	NKI-AVL HOD (Heelkundig Oncologische Disciplines) Grant	PhD Student (Stephanie Blankenstein) – Cytoreductive Treatment with Dabrafenib & Trametinib to Allow Complete Surgical Resection	PI	€ 100.000,00
2017	2018	Amgen - Unrestricted Educational Grant	Melanoma Stage III Registry	PI	€ 26.000,00
2007	2024	EORTC Melanoma Group - Unrestricted Educational Grant	EORTC 1208 – Minitub Study	PI	€ 500.000,00

**Grant Review**

From 2024	Cancer Society of New Zealand
From 2024	French National Cancer Institute
From 2023	“la Caixa” Foundation
From 2022	KWF Kankerbestrijding – Dutch Cancer Society (DCS)
From 2022	The Belgian Foundation against Cancer
From 2021	Cancer Research UK (CRUK)
From 2018	ZonMw – Dutch Organization for Health Research and Innovation
From 2014	National Science Center, Poland
From 2013	Scientific Committee ‘Amis de l’Institute J. Bordet’, Brussels, Belgium
From 2012	AIRC (Associazione Italiana per la Ricerca sul Cancro; Italian Association for Cancer Research)

**Awards**

2013	European Cancer Conference 2013 Fellowship Grant
2009	American Society of Clinical Oncology (ASCO) Merit Award for the oral presentation: <i>“Long-term Follow-up of Patients with Minimal Sentinel Node Tumor Burden (<math>\leq 0.1</math> mm) According to the Rotterdam Criteria. A study of the EORTC Melanoma Group”</i> at the ASCO Annual Meeting in Orlando, Florida, USA, June 2009
2008	Young Investigator Award for the oral presentation: <i>“Minimal Sentinel Node (SN) Tumor Burden According to the Rotterdam Criteria is the most Important Prognostic Factor for Survival in Melanoma Patients. A multicenter study in 388 SN Positive Patients”</i> at the international Sentinel Node Society Biannual Meeting in Sydney, Australia, February 2008
2007	EORTC Melanoma Group Translational Research Fellowship for the Minimal Sentinel Node Tumor Burden Study

**Selected Principal, National, Coordinating Investigatorships**

From 2024	A Phase 3, Multicentre, Randomized Controlled Trial of Selective Index Lymph Node Resection versus Therapeutic Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma. <b><u>The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3). Global Principal Investigator (PI).</u></b>
From 2019	<b><u>EORTC 2139 / Columbus-AD</u></b> - Adjuvant encorafenib & binimetinib vs. placebo in resected BRAF-positive stage II melanoma: a randomized triple-blind phase III study of the EORTC Melanoma Group (W00090GE303). <b>Principal Investigator (PI) worldwide.</b>

- 2020 – 2024 Domatinostat in combination with avelumab in patients with advanced merkel cell carcinoma progressing on anti-PD-(L)1 (**MERKLIN-2**). **Global principal investigator (PI)**.
- 2020 – 2022 Neo-adjuvant T-VEC + Nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease. (**NIVEC trial**). **Principal Investigator (PI)**.
- 2020 – 2021 Multicenter phase 1b trial testing the neoadjuvant combination of domatinostat, nivolumab and ipilimumab in IFN-gamma signature-low and IFN-gamma signature-high RECIST 1.1-measurable stage III cutaneous or unknown primary melanoma (**DONIMI**). **Sub-Principal Investigator (sub-PI)**.
- 2018 – 2021 Personalized Response-driven Adjuvant Combination (**PRADO** extension cohort) of Multicenter Phase 2 Study to Identify the Optimal neo-Adjuvant Combination of Ipilimumab and Nivolumab (OpACIN-neo). **Sub-Principal Investigator (sub-PI)**.
- From 2016 **EORTC 1612**: Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresectable or metastatic melanoma with BRAF V600 mutation: an EORTC randomized phase II study (EBIN). **Co-coordinator (EORTC-wide)**.
- 2016 – 2021 Multicenter Phase 2 Study to Identify the Optimal neo-Adjuvant Combination of Ipilimumab and Nivolumab (**OpACIN-neo**). **Sub-Principal Investigator (sub-PI)**.
- 2015 – 2021 **EORTC 1325 / Keynote-054 / MK-3475-054**: Adjuvant Immunotherapy With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK- 3475) Versus Placebo After Complete Resection of High-risk Stage III Melanoma: A Randomized, Double- Blind Phase 3 Trial of the EORTC Melanoma Group. **Local Investigator and National Coordinator**.
- 2015 – 2020 **EORTC 18081**: Adjuvant Pegylated-Interferon-alpha2b for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group. **Local Investigator and National Coordinator**.
- 2015 – 2021 Feasibility Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab (**OpACIN**). **Sub-Principal Investigator (sub-PI)**.
- From 2009 **EORTC 1208**: Melanoma Group MINITUB study: Prospective Registry of Sentinel Node (SN) Positive Melanoma Patients with Minimal SN Tumor Burden who undergo Completion Lymph Node Dissection or Nodal Observation – **Principal Investigator (EORTC-wide)**

#### Drug Approvals / Reimbursements

- 2016 Talimogene Laherparepvec (T-VEC) for stage IIIB/D, IVM1a melanoma with injectable cutaneous, subcutaneous, lymph node metastases, no brain, bone, lung or other visceral metastases.

Leading Physician on the application for reimbursement by Dutch Healthcare Authorities – Status: Approved

2017 Avelumab for irresectable stage III or metastatic stage IV Merkel Cell Carcinoma (MCC).  
Leading Physician on the application for reimbursement by Dutch Healthcare Authorities – Status: Approved

### Teaching, Mentorship and Supervision

- 2 hour weekly commitment to the MIA Multi Disciplinary Team (MDT) meetings, in which a mix of HDR students, medical students, fellows and registrars of different disciplines (for example: surgery, medical oncology, dermatology, etc.) are thought on melanoma and non-melanoma skin cancer basics as well as the latest developments.

### Higher Degree Research (HDR)

Higher Degree Student Supervision since 2011.

Primary supervisor of five PhD students and a co-supervisor for five PhD students.

Year awarded PhD	Name	Thesis Title	Role
Current, commenced 2021	Dr. Lisanne P. Zijlker	Crossing borders – on the treatment of stage III melanoma and Merkel Cell Carcinoma	Primary
Current, commenced 2020	Mr. Mees D. Egeler	Development of quality of life module for patients with metastatic melanoma	Co-supervisor
Current, commenced 2019	Dr. Sophie J.M. Reijers	Facilitating surgery for soft tissue sarcoma	Co-supervisor
Current, commenced 2019	Dr. Judith M. Versluis	Patterns of response, recurrence and progression of melanoma	Co-supervisor
Current, commenced 2018	Dr. Stephanie A. Blankenstein	Multimodality treatment in melanoma	Primary
2023	Dr. Emma H.A. Stahlie	Defining optimal oncolytic virus treatment and diagnostics in high risk melanoma patients	Primary
2023	Dr. Viola Franke	Oncolytic virus therapy in early metastatic melanoma & the importance of adequate staging	Primary
2018	Dr. Max F. Madu	Who needs adjuvant therapy in stage III Melanoma?	Primary
2017	Dr. Charlotte M.C. Oude Ophuis	Stage III Melanoma – <i>Time is relative</i>	Co-supervisor
2014	Dr. Augustinus P.D. van der Ploeg	Tumor Load in Lymph Node Positive Melanoma; <i>classification systems, prognostication models and management recommendations</i>	Co-supervisor

External independent reviewer for PhD thesis & public defence for nine PhD students.

Year awarded PhD	Name	Thesis Title	University
2024	Dr. Sonja Levy	Neuroendocrine Neoplasia Tailoring Treatment and Prognosis	Utrecht University
2024	Dr. Lodewijka H.J. Holtkamp	Stage III melanoma, a heterogeneous group of patients	University of Groningen
2021	Dr. Danique M.S. Berger	Head and Neck cutaneous melanoma: new insights in diagnostics and therapy	University of Amsterdam (UvA)
2020	Dr. Eric A. Deckers	Melanoma; The Impact of staging on treatment, prognosis & follow-up	University of Groningen
2020	Dr. Linde M. van Veenendaal	Studying Prognosis and Treatment in Patients with Neuroendocrine Neoplasia	Utrecht University
2020	Dr. Juri Teras	Loco-Regional Treatment of Cutaneous Melanoma	Tallinn University of Technology
2020	Dr. Mari van den Hout	Arming the melanoma sentinel lymph node against metastatic spread	Vrije Universiteit (VU) Amsterdam
2016	Dr. Jan M. Deroose	Two Decades of Tumor Necrosis Factor- $\alpha$ and Melphalan Based Isolated Limb Perfusion	Erasmus University Rotterdam
2013	Mrs. Loes M. Hollestein	Burden and Chemoprevention of Skin Cancer	Erasmus University Rotterdam

### Medical Students

Since 2022, I have supervised the following students enrolled in the Doctor of Medicine program within the faculty of Medicine and Health at the University of Sydney.

Year	Name	Project Title	Project Type
2024	Timothy Watson	Analysis in changes in Stages I, II and III Melanoma incidence at MIA between 2010 and 2022.	MPhil
2023	Henry Chen	Effects of neoadjuvant systemic therapy on surgical outcomes of lymph node dissections in stage III melanoma.	SMS MD Project

- Annual lecture for the Sydney Medical School (SMS) student curriculum during the Year 2 Oncology Block “Melanoma Symposium”.
- Developed questions on melanoma/sarcoma/skin cancer for year 4 MD student exams at SMS. (2023)



- Developed online resources for the Year 4 MD program at SMS with an online lecture “My approach to melanoma surgery”. (2023)

### Surgical Oncology Fellow

The department of Surgical Oncology at the Netherlands Cancer Institute (NKI) offers a competitive 12-month clinical fellowship. As a primary supervisor for the 6-month rotation of melanoma and soft tissue sarcoma I have overseen clinical commitments and duties, weekly 1:1 meetings for review of progress, education regarding the management of patients with melanoma, non-melanoma skin cancer and soft tissue sarcoma, and conduct of clinical trials and research.

- Provide support and mentorship for research projects (to be completed within 12 months).
- Provide guidance for writing successful publications
- Support conference attendance

From 2022 I have been a co-supervisor for the Melanoma Institute Australia (MIA) competitive Poche Fellowship in Melanoma and Surgical Oncology.

#### Year

2024	Mervi Rautalin	Elan Novis	
2023	Caroline Gjorup	Jade Enoch	
2022	David Coker	Ahmad Sulaiman	
2021	Caroline Drukker	Thomas Schok	
2020	Anne Bosman	Sanne Bartels	
2019	Emily Postma	Nienke Dols	
2018	Marjolein Schrijver		
2017	Iris van der Ploeg		
2016	Nieke Vermulst		
2015	Marieke Straver	Maartje Sier	

All of the above Fellows have gone on to prestigious careers.

### Advanced and Basic Registrar Education and Supervision

I have trained 42 SET2 Surgical Registrars during the period 2015 – 2021 at the Netherlands Cancer Institute (NKI) for their 3-monthly rotation with Melanoma and Surgical Oncology. Additionally, I have mentored and trained 7 advanced Surgical Oncology Registrars (SET5/6) during the period 2015 – 2021 at the Netherlands Cancer Institute. Since 2022, I have mentored and trained Basic and Advanced Surgical Trainees at the Royal Prince Alfred Hospital and Melanoma Institute Australia. I lecture to basic and advanced physician trainees in formal hospital-based training programs.

### Other Teaching, Education and Mentoring

I routinely teach for different audiences, such as General Practitioners (GP) education events, Skin Cancer practitioners, allied health (including nursing), as well as lecture at grand rounds (inter)nationally, for example at Buffet Cancer Center (2022) and Princess Margaret Hospital (2024). From 2024, I have become a mentor for the Mentoring of Australasian Surgical Students (MASS) Program of the Australasian Surgical Students Association (ASSA). The 2024 Mentee is Javid Mohammadi.



<b>Leadership, Administration, Committee and Board Membership Appointments</b>
--------------------------------------------------------------------------------

From 2024	Chair of the Royal Australasian College of Surgeons (RACS) Section of Surgical Oncology
From 2024	Chair of the Data Safety and Monitoring Committee (DSMC) of the ABC-X study
From 2023	Member of the Melanoma Disease Site Working Group (DSWG) of the Society of Surgical Oncology (SSO)
From 2023	Member of the Clinical Acceptance Committee (CAC) for the development of MIA's bespoke Electronic Medical Records (EMR) system 'TEAL', will be the first clinic to start using this system
From 2022	Chair of the Melanoma Institute Australia (MIA) Surgical Research Group (SRG)
From 2022	Research Lead for Melanoma and Surgical Oncology at RPA Institute of Academic Surgery (IAS)
From 2022	Member of Australian Melanoma Management Guidelines Working Group
From 2022	Member of Royal College of Pathologists of Australia (RCPA) Invasive Melanoma Protocol expert panel
From 2022	Member of Data Safety Monitoring Board (DSMB) for Immunotherapy Merkel Adjuvant Trial (I-MAT)
From 2022	Education Committee – Melanoma Institute Australia (MIA)
2021 – 2024	Past-Chair of European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group (MG)
From 2019	Member of Steering Committee of the Checkmate-76K trial
From 2018	Member of the American Society of Clinical Oncology (ASCO) Melanoma Guidelines Committee
2018 – 2021	Chair of the European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group (MG)
2017 – 2020	Member of European Society for Medical Oncology (ESMO) Melanoma Guidelines Committee
2017 – 2020	Chair of Dutch Melanoma Guidelines Committee
2016 – 2018	Early Career Investigator (ECI) on the European Organization for Research and Treatment of Cancer (EORTC) Board
2016 – 2020	Head of the Netherlands Cancer Institute – Antoni van Leeuwenhoek Skin Cancer and Melanoma Center
2015 – 2017	Collaborator on the 8 <sup>th</sup> Edition of Melanoma Staging System by the American Joint Committee on Cancer (AJCC)
2015 – 2018	Secretary of the European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group (MG) and Member of the Steering Committee (SC)
2015 – 2021	Member of the Clinical Academic Cancer Research Forum (CAREFOR)
2015 – 2020	Member of the Institutional Ethical Committee (EC) of the Netherlands Cancer Institute – Antoni van Leeuwenhoek (NCI-AVL).
2014 – 2020	Chairman of the Dutch National Tumor Focus Group (TFG) for Melanoma (former Dutch Melanoma Group) of the IKNL
2013 – 2020	Board Member of the Dutch National Tumor Focus Group (TFG) for Melanoma (former Dutch Melanoma Group) of the IKNL

- 2011 – 2021 Board Member of the Dutch Working group for Immunotherapy in Oncology (WIN –O) for Melanoma
- 2009 – 2014 Young Investigator Network (YIN) Representative of the European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group (MG) and Member of the Steering Committee (SC)

#### Meeting Organization, Scientific and/or Education Program Committee Membership

- 2024 – 2025 Convenor of the Section of Surgical Oncology of the 2025 Annual Scientific Congress (ASC) of the Royal Australasian College of Surgeons (RACS), Sydney, NSW, Australia
- 2023 – 2025 Steering Committee member of the 11<sup>th</sup> World Congress of Melanoma & 21<sup>st</sup> European Association of Dermato-Oncology (EADO) Congress 2025, Athens, Greece
- 2023 – 2025 European Society of Medical Oncology (ESMO) 2025 Scientific Committee member of the Melanoma and other skin tumours track, Berlin, Germany
- 2023 – 2024 Member of the Scientific Program Organising Committee of the 2024 Australasian Melanoma Conference (AMC)
- 2022 – 2024 European Society of Medical Oncology (ESMO) 2024 Scientific Committee member of the Melanoma and other skin tumours track, Barcelona, Spain
- 2022 – 2023 Australian Melanoma Conference 2023 – Surgical Program Subcommittee, March 2023, Brisbane, QLD, Australia
- 2021 Scientific Committee Member European Society for Medical Oncology (ESMO) Annual Meeting, Paris, France, September 2021
- 2020 Scientific Committee Member European Society for Medical Oncology (ESMO) Annual Meeting, Madrid, Spain, September 2020
- 2019 Scientific Committee Member European Society for Medical Oncology (ESMO) Annual Meeting, Barcelona, Spain, September 2019
- 2019 Session Chair of Oral Abstract Session for Melanoma Track. American Society for Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, U.S.A., June 2019
- 2019 8<sup>th</sup> Congress of Cancer Metastasis, San Francisco, California, USA
- 2019 2<sup>nd</sup> Cells to Surgery Meeting, Rotterdam, the Netherlands
- 2018 EORTC Melanoma Group Meeting, Amsterdam, the Netherlands
- 2017 1<sup>st</sup> Cells to Surgery Meeting, Rotterdam, the Netherlands
- 2017 Dutch Working group for Immunotherapy in Oncology (WIN –O) for Melanoma and Dutch National Tumor Focus Group (TFG) for Melanoma of IKNL yearly National Melanoma Symposium in Combination with Belgium, 2<sup>nd</sup> BeNe Meet, Rotterdam, the Netherlands
- 2015 – 2018 Member of the 2016-2017-2018 American Society of Clinical Oncology (ASCO) Cancer Education Committee Melanoma Track, Education Track Leader 2018, Member of Scientific Committee Melanoma Track 2018.
- 2015 Dutch Working group for Immunotherapy in Oncology (WIN –O) for Melanoma and Dutch National Tumor Focus Group (TFG) for Melanoma of IKNL yearly National Melanoma Symposium
- 2014 EORTC Melanoma Group Meeting, Rotterdam, the Netherlands
- 2013 Regional Symposium, Dutch Melanoma Group of IKNL, Rotterdam

2013	Regional Symposium, Dutch Melanoma Group of IKNL, Leiden
2012	First EORTC Melanoma Group Ultrasound of Lymph Node Metastases Course, Berlin, Germany
2010	EORTC Melanoma Group Meeting, Amsterdam, the Netherlands

### Professional Affiliations

From 2022	Royal Australasian College of Surgeons (RACS)
From 2022	Royal Australasian College of Surgeons (RACS) – Section of Surgical Oncology
From 2022	General Surgeons Australia (GSA)
From 2021	Society of Surgical Oncology (SSO)
From 2018	European Society for Medical Oncology (ESMO)
From 2018	Society for Melanoma Research (SMR)
2012 – 2021	European Society for Surgical Oncology (ESSO)
From 2012	Dutch Society for Surgical Oncology (NVCO; Nederlandse Vereniging voor Chirurgische Oncologie)
2011 – 2021	Dutch National Tumor Focus Group (TFG) for Melanoma (former Dutch Melanoma Group) of the IKNL, Board Member since 2013, Chair since 2015
From 2009	American Society of Clinical Oncology (ASCO)
From 2009	Dutch Surgical Society (NVVH; Nederlandse Vereniging voor Heelkunde)
From 2006	European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group (MG)

### Community and Media

#### Television

Show	Channel	Date	Story
Sky News Australia	Sky News	21.01.2023	Peer-reviewed critique goes missing amid claims of being cancelled. <a href="https://www.skynews.com.au/australia-news/use-of-unreliable-biopsies-to-test-for-melanomas-sparks-heated-debate-among-australian-cancer-experts/news-story/04cefdb8dd4ef571a702d5c58ff61864">https://www.skynews.com.au/australia-news/use-of-unreliable-biopsies-to-test-for-melanomas-sparks-heated-debate-among-australian-cancer-experts/news-story/04cefdb8dd4ef571a702d5c58ff61864</a>
RTL Nieuws	RTL 4	03.02.2020	Incidentcijfers van kanker (Dutch)
RTL Nieuws	RTL 4	05.01.2017	Antoni van Leeuwenhoek zet herpes in als middle tegen huidkanker (Dutch) <a href="https://www.rtl.nl/gezondheid/artikel/260131/antoni-van-leeuwenhoekziekenhuis-zet-herpes-als-middel-tegen-huidkanker">https://www.rtl.nl/gezondheid/artikel/260131/antoni-van-leeuwenhoekziekenhuis-zet-herpes-als-middel-tegen-huidkanker</a>
NOS Journaal	NPO 1	05.01.2017	Artsen gaan huidkanker te lijf met het koortslipvirus (Dutch) <a href="https://nos.nl/artikel/2151594-artsen-gaan-huidkanker-te-lijf-met-het-koortslipvirus">https://nos.nl/artikel/2151594-artsen-gaan-huidkanker-te-lijf-met-het-koortslipvirus</a>

#### Printed / online publications

Publication	Date	Story
Townsville Bulletin	29.05.2024	Cancer Surgery Battle <a href="https://ausprint.meltwater.com/print_clip_previewer/485370185?text=on">https://ausprint.meltwater.com/print_clip_previewer/485370185?text=on</a>
Telegraaf	06.10.2018	Reddend kankermiddel niet vergoed, patiënten in paniek (Dutch) <a href="https://www.telegraaf.nl/nieuws/2635130/reddend-kankermiddel-niet-vergoed-patienten-in-paniek">https://www.telegraaf.nl/nieuws/2635130/reddend-kankermiddel-niet-vergoed-patienten-in-paniek</a>
Telegraaf	04.10.2018	Kankerpatiënten ten einde raad: nivolumab niet vergoed (Dutch) <a href="https://www.telegraaf.nl/nieuws/2634979/kankerpatienten-ten-einde-raad-nivolumab-niet-vergoed">https://www.telegraaf.nl/nieuws/2634979/kankerpatienten-ten-einde-raad-nivolumab-niet-vergoed</a>
Telegraaf	02.10.2018	Therapie doorbreekt blokkade bij kanker (Dutch) <a href="https://www.telegraaf.nl/nieuws/2625845/therapie-doorbreekt-blokkade-bij-kanker">https://www.telegraaf.nl/nieuws/2625845/therapie-doorbreekt-blokkade-bij-kanker</a>
Telegraaf	20.04.2018	Hoop voor vaak jonge melanoom-patiënt (Dutch) <a href="https://www.telegraaf.nl/nieuws/1939588/hoop-voor-vaak-jonge-melanoom-patient">https://www.telegraaf.nl/nieuws/1939588/hoop-voor-vaak-jonge-melanoom-patient</a>
Telegraaf	20.04.2018	Triomf op huidkanker (Dutch) <a href="https://www.telegraaf.nl/nieuws/1939770/triomf-op-huidkanker">https://www.telegraaf.nl/nieuws/1939770/triomf-op-huidkanker</a>

#### Oncology Education Programs, Interviews & Podcasts

Channel	Date	Story / Link
Practice Update in Oncology	07.11.2023	SWOG S1801: Pathologic Response with Neoadjuvant vs Adjuvant Pembrolizumab in Resectable Stage IIIB-IV Melanoma <a href="https://www.practiceupdate.com/content/swog-s1801-pathologic-response-with-neoadjuvant-vs-adjuvant-pembrolizumab-in-resectable-stage-iiib-iv-melanoma/158888">https://www.practiceupdate.com/content/swog-s1801-pathologic-response-with-neoadjuvant-vs-adjuvant-pembrolizumab-in-resectable-stage-iiib-iv-melanoma/158888</a>
VuMedi	03.11.2023	ESMO 2023 Insights: “A Surgeon’s Perspective: Do We Still Need Melanoma Surgery in the Era of Risk Scores Stratification and Systemic Therapy?” <a href="https://www.vumedi.com/video/esmo-2023-insights-a-surgeons-perspective-do-we-still-need-melanoma-surgery-in-the-era-of-risk-score/">https://www.vumedi.com/video/esmo-2023-insights-a-surgeons-perspective-do-we-still-need-melanoma-surgery-in-the-era-of-risk-score/</a>
Melanoma Institute Australia – Education Portal	28.09.2023	Podcast: Melanoma: When do I scan? <a href="https://melanomaeducation.org.au/courses/?s=akkooi&amp;ref=course">https://melanomaeducation.org.au/courses/?s=akkooi&amp;ref=course</a>
Melanoma Institute Australia – Education Portal	13.09.2023	Podcast: Getting the pathology right: Melanoma in General Practice <a href="https://melanomaeducation.org.au/courses/melanoma169/">https://melanomaeducation.org.au/courses/melanoma169/</a>
Met het Mes aan Tafel	07.09.2023	Podcast: Het Melanoom (Dutch) <a href="https://methetmesaantafel.buzzsprout.com/1019002/13527415-het-melanoom-met-alexander-van-akkooi">https://methetmesaantafel.buzzsprout.com/1019002/13527415-het-melanoom-met-alexander-van-akkooi</a>
Practice Update in Oncology	27.06.2023	Response-Directed Surgery and Adjuvant Therapy in Stage III Melanoma <a href="https://www.practiceupdate.com/content/response-directed-surgery-and-adjuvant-therapy-in-stage-iii-melanoma/153808">https://www.practiceupdate.com/content/response-directed-surgery-and-adjuvant-therapy-in-stage-iii-melanoma/153808</a>

Melanoma Institute Australia – Education Portal	14.03.2023	Podcast: Neoadjuvant immunotherapy: Revolutionising melanoma treatment <a href="https://melanomaeducation.org.au/courses/melanoma183/">https://melanomaeducation.org.au/courses/melanoma183/</a>
The Video Journal of Oncology (VCOncology)	28.04.2021	WCM/EADO 2021 – Immunotherapies for satellite or ITM melanoma <a href="https://www.vjoncology.com/video/1d697a5kfk-immunotherapies-for-satellite-or-itm-melanoma/">https://www.vjoncology.com/video/1d697a5kfk-immunotherapies-for-satellite-or-itm-melanoma/</a>
The Video Journal of Oncology (VCOncology)	19.04.2021	WCM/EADO 2021 – Serum NSE levels as a biomarker in MCC <a href="https://www.vjoncology.com/video/ocwwmi2dhdc-serum-nse-levels-as-a-biomarker-in-mcc/">https://www.vjoncology.com/video/ocwwmi2dhdc-serum-nse-levels-as-a-biomarker-in-mcc/</a>
The Video Journal of Oncology (VCOncology)	19.04.2021	WCM/EADO 2021 – Real-world analysis of T-VEC for melanoma <a href="https://www.vjoncology.com/video/hqgxod7ldkc-real-world-analysis-of-t-vec-for-melanoma/">https://www.vjoncology.com/video/hqgxod7ldkc-real-world-analysis-of-t-vec-for-melanoma/</a>
The Video Journal of Oncology (VCOncology)	14.10.2020	EADO 2020 – Neoadjuvant approaches in melanoma <a href="https://www.vjoncology.com/video/l9j7ks6qtja-neoadjuvant-approaches-in-melanoma/">https://www.vjoncology.com/video/l9j7ks6qtja-neoadjuvant-approaches-in-melanoma/</a>
Practice Update in Oncology	28.04.2020	Melanoma in the COVID-19 Era: Locally Advanced Cancer <a href="https://www.practiceupdate.com/c/99514/48/21?fbclid=IwZXh0bgNhZW0CMtAAAR2-L9n199tIL_e9PFGMtW9Hwbj4YAxwDOOMoUVW99o4cmnxv_i4QoIXQM_aem_AcPJ4hCkiKS3puTZFK_xo-jlyhZK1tLCuBNBo77Av1D-0oh000wMonc3VGOTKyF-47KIZQq6EkaPcw-a-vQjA8">https://www.practiceupdate.com/c/99514/48/21?fbclid=IwZXh0bgNhZW0CMtAAAR2-L9n199tIL_e9PFGMtW9Hwbj4YAxwDOOMoUVW99o4cmnxv_i4QoIXQM_aem_AcPJ4hCkiKS3puTZFK_xo-jlyhZK1tLCuBNBo77Av1D-0oh000wMonc3VGOTKyF-47KIZQq6EkaPcw-a-vQjA8</a>
Practice Update in Oncology	27.04.2020	Melanoma in the COVID-19 Era: Surgery for Early-Stage Cancer <a href="https://www.practiceupdate.com/c/99513/48/21?fbclid=IwZXh0bgNhZW0CMtAAAR1bS0k3-A4oOBAHjuNcSeZr4tOiVb-0KXssMC8utf_7VfudJVQABJp2aik_aem_AfqTvVGZsVoHcgauN_gceSE9sDmrJi-GdT8CwooF3zcpDegPercbLOYdYo7p-lyGQT1ksgbjmpZYHN9l-1nQ9Pea">https://www.practiceupdate.com/c/99513/48/21?fbclid=IwZXh0bgNhZW0CMtAAAR1bS0k3-A4oOBAHjuNcSeZr4tOiVb-0KXssMC8utf_7VfudJVQABJp2aik_aem_AfqTvVGZsVoHcgauN_gceSE9sDmrJi-GdT8CwooF3zcpDegPercbLOYdYo7p-lyGQT1ksgbjmpZYHN9l-1nQ9Pea</a>
Practice Update in Oncology	16.03.2020	Treatment of Merkel Cell Carcinoma <a href="https://www.practiceupdate.com/content/treatment-of-merkel-cell-carcinoma/90913/45/1/3">https://www.practiceupdate.com/content/treatment-of-merkel-cell-carcinoma/90913/45/1/3</a>
VuMedi	28.11.2019	Spectrum of Micrometastasis in Melanoma Sentinel Lymph Nodes: SN Tumour Burden Helps Distinguish Between Higher & Lower Risk SN+ Disease <a href="https://www.vumedi.com/channel/international-congress-on-cancer-metastasis/tab/current-management-of-melanoma-patients/video/spectrum-of-micrometastasis-in-melanoma-sentinel-lymph-nodes-sn-tumor-burden-helps-distinguish-between/">https://www.vumedi.com/channel/international-congress-on-cancer-metastasis/tab/current-management-of-melanoma-patients/video/spectrum-of-micrometastasis-in-melanoma-sentinel-lymph-nodes-sn-tumor-burden-helps-distinguish-between/</a>
eCancer	21.03.2019	Latest updates in melanoma research <a href="https://ecancer.org/en/video/7723-latest-updates-in-melanoma-research">https://ecancer.org/en/video/7723-latest-updates-in-melanoma-research</a>
Practice Update in Oncology	01.02.2019	Practice-Changing Developments in Stage III Melanoma <a href="https://www.practiceupdate.com/content/practice-changing-developments-in-stage-iii-melanoma/75121">https://www.practiceupdate.com/content/practice-changing-developments-in-stage-iii-melanoma/75121</a>

Practice Update in Oncology	06.06.2018	ASCO 2018: Implications for the clinician of the new AJCC staging system for melanoma <a href="https://www.practiceupdate.com/content/asco-2018-implications-for-the-clinician-of-the-new-ajcc-staging-system-for-melanoma/69088/45/1/3">https://www.practiceupdate.com/content/asco-2018-implications-for-the-clinician-of-the-new-ajcc-staging-system-for-melanoma/69088/45/1/3</a>
eCancer	04.06.2018	Updates in melanoma from ASCO 2018 <a href="https://ecancer.org/en/video/6952-updates-in-melanoma-from-asco-2018">https://ecancer.org/en/video/6952-updates-in-melanoma-from-asco-2018</a>
eCancer	10.09.2017	New strategies in melanoma care <a href="https://ecancer.org/en/video/6255-new-strategies-in-melanoma-care">https://ecancer.org/en/video/6255-new-strategies-in-melanoma-care</a>

### Presentations

- 2024 *The evolution of the role of surgery for patients with resectable macroscopic lymphadenopathy.*  
Invited Faculty, Victoria Comprehensive Cancer Centre (VCCC), Locoregionally Advanced Melanoma Symposium, Melbourne, VIC, Australia, April 2024
- 2024 *The Great Debate - Targeted Approach to the Lymph Nodes after Neoadjuvant Immunotherapy for Melanoma: PRO*  
Invited Faculty, Society of Surgical Oncology (SSO) Annual Meeting, Atlanta, GA, U.S.A., March 2024
- 2024 *Provision of surgical services by GPs and other specialists in skin cancer treatment.*  
Invited speaker, Melanoma Institute Australia (MIA) Hybrid GP Education Event, Sydney, NSW, Australia, February 2024
- 2024 *Neo-Adjuvant Immunotherapy for Melanoma*  
Invited Faculty, Grand Rounds, Princess Margaret Hospital Melanoma Unit, Toronto, ON, Canada, Hybrid, January 2024
- 2023 *Developments in Adjuvant and Neo-Adjuvant Therapies for Melanoma*  
Invited Speaker, GD Path, Webinar, November 2023
- 2023 *Loco-regional treatment options for in-transits*  
Invited Speaker, 42<sup>nd</sup> Congress of the European Society of Surgical Oncology (ESSO), Florence, Italy, October 2023
- 2023 *The promise of neo-adjuvant immunotherapy in Melanoma*  
Invited speaker, seminar at Careggi University Hospital, University of Florence, Florence, Italy, October 2023
- 2023 *Do we still need surgery in the era of risk scores stratification and systemic therapy? A Surgeon's perspective.*  
Invited Faculty, European Society of Medical Oncology (ESMO) Annual Meeting, Madrid, Spain, October 2023
- 2023 *Neo-Adjuvante Systeem (NAS) Therapie (Dutch)*  
Nascholing: "Melanoom: waar werelden elkaar ontmoeten" (Dutch)  
Invited Speaker, Netherlands Cancer Institute, Amsterdam, the Netherlands, October 2023



- 2023 *Controversies around Sentinel Lymph Node Biopsy (SLNB) in Melanoma*  
Invited Speaker, GD Path, Webinar, September 2023
- 2023 *The promise of neo-adjuvant immunotherapy in Melanoma*  
Invited Speaker, New Zealand Society for Oncology (NZSO) Annual Conference, Plenary Meeting, Ahuriri/Napier, Hawke's Bay, New Zealand, September 2023.
- 2023 *Peri-operative immunotherapy in Melanoma*  
Invited Speaker, New Zealand Society for Oncology (NZSO) Annual Conference, MSD Breakfast Symposium, Ahuriri/Napier, Hawke's Bay, New Zealand, September 2023.
- 2023 *Adjuvant and Neo-Adjuvant Therapy and Contemporary Melanoma Surgery*  
Invited Speaker, New Zealand Society for Oncology (NZSO) Annual Conference, Melanoma Special Interest Group (SIG), Ahuriri/Napier, Hawke's Bay, New Zealand, September 2023.
- 2023 *An overview of melanoma*  
Invited Speaker, Southern Adelaide Skin Society (SASS), Webinar, July 2023
- 2023 *Unveiling Present and Future Treatment Strategies for Early Stage BRAF-Mutant Melanoma*  
Faculty, Pierre Fabre Satellite Symposium / Post-Chicago, Munich, Germany, June 2023
- 2023 *Sentinel Lymph Node Biopsy (SLNB)*  
Invited Speaker, Webinar GD Path, June 2023
- 2023 *Implications of the evolving systemic therapy landscape in melanoma on surgery*  
Invited Speaker, Hybrid, UK Oncology Forum, Birmingham, UK, June 2023
- 2023 *Neo-adjuvant immunotherapy: a gamechanger for melanoma patients*  
Together with Prof. Georgina Long, AO  
Invited Speaker, Current Trends in Immuno-Oncology (CTIO), Sydney, NSW, Australia, April 2023
- 2023 *Plenary: Neo-adjuvant immunotherapy: a gamechanger for melanoma patients*  
Together with Prof. Georgina Long, AO and Prof. Richard Scolyer, AO.  
Invited Speaker, the Australasian Melanoma Conference 2023, Brisbane, QLD, Australia, March 2023
- 2023 *Management of In-transit Melanoma*  
Invited Speaker, the Australasian Melanoma Conference 2023, Brisbane, QLD, Australia, March 2023
- 2023 *A practical guide to sentinel node biopsy – Metro surgeon*  
Invited Speaker, the Australasian Melanoma Conference 2023, Brisbane, QLD, Australia, March 2023
- 2023 *Surgical management of Merkel cell carcinoma*  
Invited Speaker, NSW Plastic Surgery Registrars Training Day, Sydney, NSW, Australia, March 2023
- 2023 *Changes in Early Melanoma Management*  
Invited speaker, Cancer Nurses Society of Australia (CNSA), Webinar, Sydney NSW, Australia, March 2023
- 2023 *Practical surgery for managing early melanoma*



- Invited speaker, Melanoma Institute Australia (MIA) Hybrid GP Education Event, Sydney, NSW, Australia, March 2023
- 2022 *How to customize adjuvant treatment in melanoma*  
Faculty, European Society for Medical Oncology (ESMO) Asia meeting, Singapore, December 2022
- 2022 *BRAF-mut melanoma state of science and where to next*  
Invited Faculty, Emerging Treatment Paradigms in BRAF-mut CRC & Melanoma, Educational Symposium. Singapore, December 2022
- 2022 *Management of Metastatic Nodal Disease*  
Invited Faculty, General Surgeons Australia (GSA), Annual Scientific Meeting (ASM), Darling Harbor, Sydney, NSW, Australia, October 2022
- 2022 *Melanoma Stage IV*  
Invited Faculty, General Surgeons Australia (GSA), Annual Scientific Meeting (ASM), Trainees' Day, Darling Harbor, Sydney, NSW, Australia, October 2022
- 2022 *Merkel Cell Carcinoma (MCC)*  
Invited Faculty, General Surgeons Australia (GSA), Annual Scientific Meeting (ASM), Trainees' Day, Darling Harbor, Sydney, NSW, Australia, October 2022
- 2022 *Neo-adjuvant Therapy in Melanoma*  
Invited Faculty, Solid Tumors Education and Management (STeAM), Sydney, NSW, Australia, September 2022
- 2022 *De-escalation in Melanoma Surgery*  
Invited Speaker, Royal Prince Alfred Hospital (RPAH), Grand Rounds, Camperdown, Sydney, NSW, Australia, August 2022
- 2022 *Inaugural Lecture : The Future of Melanoma and Surgical Oncology*  
University of Sydney, Camperdown, Sydney, NSW, Australia, July 2022
- 2022 *An overview of melanoma*  
Invited Speaker, 2022 Nurse Melanoma Symposium, Melanoma Institute Australia, Wollstonecraft, Sydney, NSW, Australia, July 2022
- 2022 *Stage II Melanoma: Shifting the treatment paradigm as a consequence of systemic therapy developments.*  
Invited Speaker, 3<sup>rd</sup> Cells to Surgery, Rotterdam Skin Cancer Congress, Rotterdam, the Netherlands, July 2022, Hybrid.
- 2022 *Case-Based Panel: Challenging Multidisciplinary Care in Advanced Skin Cancers*  
Invited Faculty, American Society for Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, U.S.A., June 2022
- 2022 *Stage II Melanoma: Developments as a result from advances in systemic therapies*  
Invited Speaker, Melanoma Focus Virtual Regional Meeting, May 2022
- 2022 *Neoadjuvant therapy and the place for surgery*  
Invited Speaker, 90<sup>th</sup> Annual Scientific Congress (ASC) of the Royal Australasian College of Surgeons (RACS), Brisbane, Queensland, Australia, May 2022
- 2022 *Surgical Management of Melanoma*  
Faculty, Updates in skin cancer diagnosis and management, hybrid GP education evening, Melanoma Institute Australia, Sydney, NSW, Australia, April 2022
- 2022 *Surgery – Adjuvant RT*

- Invited Speaker, 2<sup>nd</sup> International Symposium on Merkel Cell Carcinoma (MCC), Seattle, WA, U.S.A., April 2022 (Hybrid)
- 2022 *When to perform surgery for stage IV*
- Invited Speaker, 18<sup>th</sup> European Association of Dermato-Oncology (EADO) Congress, Sevilla, Spain, April 2022 (Hybrid)
- 2022 *Treatment of Advanced Locoregional Melanoma*
- Invited Speaker, 18<sup>th</sup> European Association of Dermato-Oncology (EADO) Congress, Sevilla, Spain, April 2022 (Hybrid)
- 2022 *Stage III malignant melanoma: surgery first? No*
- Invited Speaker, 18<sup>th</sup> European Association of Dermato-Oncology (EADO) Congress, Sevilla, Spain, April 2022 (Hybrid)
- 2022 *In-Transit Metastases*
- Invited Speaker, Advances in diagnostics and therapy of melanoma and other skin cancers, March 2022, Warsaw, Poland (Hybrid)
- 2022 *Stage II Melanoma: A new research focus.*
- Invited Speaker, International Melanoma Working Group (IMWG), AIM at Melanoma Foundation, 2022 Spring Meeting, March 2022 (Virtual)
- 2022 *Developments in melanoma surgery as a result from advances in systemic therapies.*
- Invited Speaker, Buffet Cancer Center Grand Rounds, Nebraska Medicine Fred & Pamela Buffett Cancer Center, Omaha, NE, U.S.A., March 2022 (Virtual)
- 2021 *Stage III Melanoma and Non-Melanoma Skin Cancer (NMSC) : Future Perspectives*
- Invited Speaker, Melanoma Symposium – Farewell Alexander, Netherlands Cancer Institute, Amsterdam, the Netherlands, October 2021 (Hybrid)
- 2021 *New principles of integrating surgical and systemic therapy in melanoma?*
- Invited Speaker, 2021 UK Oncology Forum (Virtual)
- 2021 *Surgical Treatment*
- Invited Speaker, 30<sup>th</sup> Congress of European Academy of Dermatology and Venereology (EADV), September 2021 (Virtual)
- 2021 *Current trials and future implications*
- Invited Faculty, European Society of Medical Oncology (ESMO) Annual Meeting, Paris, France, September 2021 (Hybrid)
- 2021 *Is there still a role for CLND after positive SNB or surgery in stage IV melanoma?*
- Invited Faculty, 14<sup>th</sup> Nordic Meeting of the Nordic Melanoma Group, Helsinki, Finland, September 2021
- 2021 *Treatment option for in-transit and locoregionally advanced melanoma, including neo-adjuvant systemic therapy (NAST).*
- Invited Faculty, 14<sup>th</sup> Nordic Meeting of the Nordic Melanoma Group, Helsinki, Finland, September 2021
- 2021 *Neoadjuvant Therapy in Melanoma – Keynote Lecture*
- Invited Visitor, Royal Australasian College of Surgeons (RACS) 89<sup>th</sup> Annual Scientific Congress (ASC), Melbourne, Australia, May 2021 (Virtual)
- 2021 *What are the important endpoints in planning and interpreting adjuvant and neoadjuvant trials.*

- Invited Visitor, Royal Australasian College of Surgeons (RACS) 89<sup>th</sup> Annual Scientific Congress (ASC), Melbourne, Australia, May 2021 (Virtual)
- 2021 *Surgery of metastatic melanoma: Case presentation and discussion.*
- Invited Faculty, 10<sup>th</sup> World Congress of Melanoma & 17th EADO (European Association of Dermato-Oncology) Congress 2021, Rome, Italy, April 2021 (Virtual)
- 2021 *Controversies in melanoma management. Intense follow-up evaluations improve survival !? – No*
- Invited Faculty, 10<sup>th</sup> World Congress of Melanoma & 17th EADO (European Association of Dermato-Oncology) Congress 2021, Rome, Italy, April 2021 (Virtual)
- 2021 *Sentinel node tumor burden (and more) in stage III melanoma: lessons learned and opportunities*
- Invited Faculty, 10<sup>th</sup> World Congress of Melanoma & 17th EADO (European Association of Dermato-Oncology) Congress 2021, Rome, Italy, April 2021 (Virtual)
- 2021 *Recent developments in neo-adjuvant systemic therapy for melanoma*
- Scottish Skin Cancer Annual Meeting
- Invited Faculty, March 2021, Virtual
- 2021 *ESSO (European Society of Surgical Oncology) Webinar on Controversies in the Management of Stage III Melanoma*
- Invited Faculty, February 2021, Virtual
- 2020 *Neoadjuvance in the treatment of melanoma, current status*
- Invited Faculty, of II Brazilian Congress of Gynecologic Oncology, II MoonShot Brazil Sul and VIII International IOP Congress. Curitiba, Brazil, November 2020 (Virtual)
- 2020 *What is the role of surgery in the modern treatment of stage III melanoma*
- Invited Faculty, European Society for Medical Oncology (ESMO) Asia meeting, Singapore, November 2020 (Virtual)
- 2020 *Are Neoadjuvant trials for translational research or a registration pathway for new treatments?*
- Invited Faculty, 16<sup>th</sup> Annual EADO (European Association of Dermato-Oncology) Congress, Virtual Meeting, October 2020
- 2020 *Neo-adjuvant approaches*
- Invited Faculty, 16<sup>th</sup> Annual EADO (European Association of Dermato-Oncology) Congress, Virtual Meeting, October 2020
- 2020 *A retrospective chart review study of real-world use of talimogene laherparepvec in unresectable stage IIIB-IVM1a melanoma in four European countries*
- Selected free oral presentation, 16<sup>th</sup> Annual EADO (European Association of Dermato-Oncology) Congress, Virtual Meeting, October 2020
- 2019 *Stage III Melanoma: How to improve the patient's management?*
- Invited Faculty, 25<sup>th</sup> National Congress of IMI (Italian Melanoma Intergroup), Bologna, Italy, November 2019
- 2019 *Spectrum of micrometastasis in melanoma sentinel lymph nodes.*
- Invited Faculty, 8<sup>th</sup> Biannual International Congress on Cancer Metastasis, San Francisco, CA, U.S.A., October 2019
- 2019 *Perioperative Therapy in melanoma : the role of surgery*

- Invited Faculty, European Society of Medical Oncology (ESMO) Annual Meeting, Barcelona, Spain, September 2019
- 2019 *Neo-adjuvant therapy*
- Invited Faculty, European Society of Medical Oncology (ESMO) Annual Meeting, Barcelona, Spain, September 2019
- 2019 *Is there still a role for the dissection of additional lymphnodes?*
- Invited Faculty, 13<sup>th</sup> Grupo Brasileiro de Melanoma (GBM) Biannual Brazilian Melanoma Conference, Florianopolis, Brazil, August 2019.
- 2019 *Perspectives, Difficulties and Limitations of neoadjuvancy*
- Invited Faculty, 13<sup>th</sup> Grupo Brasileiro de Melanoma (GBM) Biannual Brazilian Melanoma Conference, Florianopolis, Brazil, August 2019.
- 2019 *Limb restricted disease: limb perfusion or intra lesional therapies?*
- Invited Faculty, 13<sup>th</sup> Grupo Brasileiro de Melanoma (GBM) Biannual Brazilian Melanoma Conference, Florianopolis, Brazil, August 2019.
- 2019 *What role does surgery have in the immunotherapy era?*
- Melanoma Focus Regional Meeting, Invited Faculty, Leeds, U.K., May 2019
- 2019 *Identification of high risk melanoma patients with regard to systemic treatment*
- Melanoma Focus Regional Meeting, Invited Faculty, Leeds, U.K., May 2019
- 2019 *Neo-Adjuvant Therapy for Melanoma*
- Faculty, 2<sup>nd</sup> Cells to Surgery Meeting, Rotterdam, the Netherlands, February 2019
- 2018 *Surgery for Melanoma*
- Skin Cancer Week, IPO, Invited Faculty Porto, Portugal, December 2018
- 2018 *Great Debate: Argument for Adjuvant Therapy*
- Melanoma Bridge 2018, Invited Faculty, Naples, Italy, December 2018
- 2018 *Changing landscape in surgery for stage III melanoma in the era of (neo-)adjuvant treatments.* Italian Melanoma Intergroup (IMI) XXIV National Congress, Invited Faculty Lecture, Bari, Italy, November 2018
- 2018 *BRAF Mutation Testing in the Evolving Melanoma Treatment Landscape.* European Congress of Pathology (ECP), Satellite Symposium, Invited Faculty, Bilbao, Spain, September 2018.
- 2018 *Oncolytic Immunotherapy – What does it mean for patients with early metastatic melanoma?* 8<sup>th</sup> European Post-Chicago Melanoma/Skin Cancer Meeting, Satellite Symposium, Invited Faculty, Munich, Germany, June 2018.
- 2018 *T-VEC therapy for In-Transit Metastases, Neo-Adjuvant and Adjuvant Treatment.* Keynote Speaker, 37<sup>th</sup> Congress of the Scandinavian Association of Plastic Surgeons, Copenhagen, Denmark, June 2018
- 2018 *New AJCC Staging System, Micrometastases in Lymph Nodes.* Keynote Speaker, 37<sup>th</sup> Congress of the Scandinavian Association of Plastic Surgeons, Copenhagen, Denmark, June 2018
- 2018 *Extent of Surgery for Stage III Melanoma: How Much is Appropriate?* Faculty, American Society for Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, U.S.A., June 2018
- 2018 *Domburg Dagen: Pro-Con Debate on Sentinel Node for Melanoma.* Invited Speaker, Domburg, the Netherlands, May 2018.

- 2018 *PRISM: PROgressing Individualised treatment Strategies in Melanoma*. Faculty, London, United Kingdom, March 2018.
- 2018 *Masterclass Melanoma: Wide Local Excision and Sentinel Node*. Invited Speaker, Amersfoort, the Netherlands, January 2018.
- 2017 *Neo-Adjuvant Strategies in Stage III Melanoma*. Invited Faculty, 1<sup>st</sup> European Society for Medical Oncology (ESMO) Immuno Oncology (IO) Congress, Geneva, Switzerland, December 2017.
- 2017 *Sentinel Lymph Node Biopsy in Melanoma: Is the Paradigm Shifting?* Invited Faculty, 21<sup>st</sup> National Meeting of the Russian Society of Clinical Oncology (RUSSCO), Moscow, Russia, November 2017.
- 2017 *Controversies on lymph node management*. Invited Faculty, 9<sup>th</sup> World Congress of Melanoma (WCM) / 14<sup>th</sup> International Congress of the Society for Melanoma Research (SMR), Brisbane, Australia, October 2017.
- 2017 *Loco-regional therapies: ECT, PV-10, T-VEC*. Faculty, 12<sup>th</sup> Grupo Brasileiro de Melanoma (GBM) Biannual Brazilian Melanoma Conference, Sao Paulo, Brazil, August 2017.
- 2017 *Why should we stop emptying patients with SN+ disease?* Faculty, 12<sup>th</sup> Grupo Brasileiro de Melanoma (GBM) Biannual Brazilian Melanoma Conference, Sao Paulo, Brazil, August 2017.
- 2017 *Mucosal melanoma – should surgery follow the same principles as cutaneous melanoma?* Faculty, 12<sup>th</sup> Grupo Brasileiro de Melanoma (GBM) Biannual Brazilian Melanoma Conference, Sao Paulo, Brazil, August 2017.
- 2017 *Epidemiology & Early detection – Europe*. Faculty, 12<sup>th</sup> Grupo Brasileiro de Melanoma (GBM) Biannual Brazilian Melanoma Conference, Sao Paulo, Brazil, August 2017.
- 2017 *How long to perform SN after diagnosis?* Faculty, 12<sup>th</sup> Grupo Brasileiro de Melanoma (GBM) Biannual Brazilian Melanoma Conference, Sao Paulo, Brazil, August 2017.
- 2017 *PRISM: PROgressing Individualised treatment Strategies in Melanoma*. Faculty, London, United Kingdom, March 2017.
- 2017 *Immuno-Oncology*. Session Chair. EORTC Groups Annual Meeting (EGAM), Brussels, Belgium, March 2017.
- 2017 *Loco-Regional Treatment*. Invited Speaker / Panel. EORTC Groups Annual Meeting (EGAM), Brussels, Belgium, March 2017.
- 2017 *Sentinel node and completion node dissection: to do or not to do?!?!* Invited Speaker. Regional Meeting of IKNL National Tumor Focus Group (TFG) for Melanoma, Leeuwarden, the Netherlands, Februari, 2017.
- 2017 *This house believes that high-risk stage III melanoma should NOT be treated with adjuvant ipilimumab after complete resection*. Moderator. European Cancer Congress (ECCO2017), Amsterdam, the Netherlands, January 2017.
- 2017 *Melanoma: Critical Review of Presented Trials and Implications in Practice – Surgical and Radiotherapy Oncology Perspective*. Invited Speaker. European Cancer Congress (ECCO2017), Amsterdam, the Netherlands, January 2017.
- 2016 *Systemic versus regional treatment in the modern era of melanoma*. Faculty. 2<sup>nd</sup> European Society for Medical Oncology (ESMO) Asia meeting, Singapore, December 2016.

- 2016 *Developments in stage III Melanoma: Lymph node dissections, T-VEC and adjuvant therapy.* Invited Speaker. 6<sup>th</sup> Annual Meeting of the Dutch Working group for Immunotherapy in Oncology (WIN –O) for Melanoma. Ede, the Netherlands, November 2016.
- 2016 *Merkel Cell Carcinoma.* Invited Speaker, Neuro-endocrine carcinoma (NEC) and neuro-endocrine tumor (NET) patient's society day 2016, Amersfoort, the Netherlands, November 2016
- 2016 *Sentinel Node and Node Dissections, Guidelines and Update.* Invited Speaker, Regional Meeting of IKNL National Tumor Focus Group (TFG) for Melanoma, Amsterdam, the Netherlands, October 2016
- 2016 *What are the option for managing loco-regional disease and how can they be improved?* Invited speaker, Focus on Melanoma Meeting, Royal College of Physicians, London, U.K. October 2016.
- 2016 *Surgical Management for High-Risk Disease: Is There a Standard?* Educational Session, Faculty, American Society for Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, U.S.A., June 2016
- 2016 *Are SN databases comparable?* Invited Speaker, 10<sup>th</sup> International Sentinel Node Society Meeting, Milan, Italy, April-May 2016.
- 2015 *How new drugs are changing the role of surgery in melanoma.* Invited Speaker, 1<sup>st</sup> European Society for Medical Oncology (ESMO) Asia meeting, Singapore, December 2015.
- 2015 *Adjuvant Therapy for High Risk Stage II / III Melanoma.* Invited Speaker, 5<sup>th</sup> Annual Meeting of the Dutch Working group for Immunotherapy in Oncology (WIN –O) for Melanoma. Ede, the Netherlands, November 2015.
- 2015 *Ultrasound guided FNAC of Melanoma Lymph Nodes: The Latest Developments & Staging in Melanoma: The Era of (Neo-)Adjuvant Therapies.* Faculty, EUmeet, Oslo, Norway, November 2015.
- 2015 *Incurable Melanoma Nowadays: Surgery in the Light of the Fab Four.* Invited Speaker, Melanoma and Sarcoma Educational Day of the Dutch Society for Surgical Oncology, Tiel, the Netherlands, October 2015.
- 2015 *Sentinel lymph node biopsy as a surgical procedure. Outweighing risk and benefits in certain clinical settings.* Faculty, 1<sup>st</sup> What's New in Skin Cancer Meeting, Lisbon, Portugal, September 2015.
- 2015 *Surgery and more.* Invited Speaker. European School of Oncology (ESO) Session on Melanoma during 1<sup>st</sup> Russian International Oncology Forum, "White Nights of St. Petersburg 2015", St. Petersburg, Russia, June 2015.
- 2015 *Surgery for Melanoma.* 44<sup>th</sup> Annual NCI-AVL Surgeon's Week, Amsterdam, the Netherlands, February 2015.
- 2014 *MSLT-1 Final Analysis: To do or not to do a Sentinel Node.* Invited Speaker. 4<sup>th</sup> Annual Meeting of the Dutch Working group for Immunotherapy in Oncology (WIN –O) for Melanoma. Nunspeet, the Netherlands, November 2014.
- 2014 *Surgery for stage IV Melanoma.* Faculty, Updates in the Management of Melanoma – European School of Oncology (ESO). Bucharest, Romania, October 2014.



- 2014 *Surgical Treatment on Lymph Node Metastases*. Faculty, Updates in the Management of Melanoma – European School of Oncology (ESO). Bucharest, Romania, October 2014.
- 2014 *Management of in-transit metastases: (Loco)-regional or Medical approach?* Invited Speaker, 10<sup>th</sup> EADO (European Association of Dermato-Oncology) meeting, Vilnius, Lithuania, May 2014.
- 2014 *Sentinel Node (SN) for Melanoma: Controversy between MSLT-1 and Dutch National Guidelines*. Invited Speaker, Dermato-oncology Conference, Spa, Belgium, March 2014.
- 2014 *EORTC 1208: Minitub. An Update*. Invited Speaker. Danish Melanoma Group, Copenhagen, Denmark, March 2014.
- 2014 *Ultrasound (US) – guided FNAC (Fine Needle Aspiration Cytology) of Melanoma Lymph Nodes; the Latest Developments*. Faculty, EUmeet, Oslo, Norway, February 2014.
- 2014 *Diagnostics, Treatment and Referral; Organization of Health Care for Stage I, II & III Melanoma Patients in the Netherlands*. Webcast, February 2014.
- 2013 *Ultrasound (US) – guided FNAC (Fine Needle Aspiration Cytology) of the Sentinel Node (SN) in 1000 consecutive Melanoma patients*. Oral Presentation. Biannual European Cancer Conference – European Society of Medical Oncology (ECCO-ESMO) meeting, Amsterdam, the Netherlands, September 2013.
- 2013 *Pro-con debate: Sentinel node of Melanoma: Standard of Care?* Oral Presentation, Regional Melanoma Symposium, Leiden, the Netherlands, May 2013.
- 2013 *Half of positive Sentinel Nodes (SN) in Melanoma can be correctly identified pre-operatively by Ultrasound (US) – guided Fine Needle Aspiration Cytology (FNAC)*. Oral Presentation, 2<sup>nd</sup> Paris Melanoma Conference, Paris, France, May 2013.
- 2012 *Advanced Melanoma – Recommended Strategy for Node Positive or Metastatic Disease*. Invited Speaker, 4<sup>th</sup> Clinical Oncology Update, Krakow, Poland, May 2012.
- 2012 *Sentinel Node Biopsy: Lessons from an European – Australian Comparison*. Faculty, 1<sup>st</sup> Paris Melanoma Meeting, Paris, France, March 2012.
- 2011 *Sentinel Node Staging: Controversies*. Faculty, euMelanoma Meeting, Oslo, Norway, November 2011.
- 2011 *Inguinal lymph node dissection for melanoma: perform it or not?* Oral Presentation. 1<sup>st</sup> Annual Meeting of the Dutch Working group for Immunotherapy in Oncology (WIN –O) for Melanoma. Ede, the Netherlands, November 2011.
- 2011 *Minimal Tumor Burden of Sentinel Nodes (SN): An International Multicentric Study*. Invited Speaker. 17<sup>th</sup> Italian Melanoma Intergroup (IMI) Annual Meeting, Milan, Italy, October 2011.
- 2011 *MINITUB; Prospective Registration Study on Sentinel Node (SN) Positive Patients with Minimal SN Tumor Burden Managed without Completion Lymph Node Dissection (CLND)*, Oral Presentation, EORTC Groups Annual Meeting (EGAM), Brussels, Belgium, March 2011.
- 2010 *Complete lymph node dissection; mandatory or an option for whom?* Invites Speaker. Perspectives in Melanoma, Amsterdam, the Netherlands, September 2010.



- 2010 *MINITUB; Prospective Registration Study on Sentinel Node (SN) Positive Patients with Minimal SN Tumor Burden Managed without Completion Lymph Node Dissection (CLND)*, Oral Presentation, EORTC Melanoma Group Meeting, Villejuif, France, April 2010.
- 2010 *Excellent prognosis of patients with minimal SN tumor burden according to Rotterdam Criteria*. Oral Presentation, EORTC Melanoma Group Meeting, Villejuif, France, April 2010.
- 2009 *Unusual first presentation of metastatic pancreatic cancer as skin metastases in a burn patient*. Oral Presentation, Dutch Society of Burn Care Annual Meeting, Groningen, the Netherlands, November 2009.
- 2009 *Excellent long-term survival of patients with minimal sentinel node tumor burden (<0.1mm) according to the Rotterdam Criteria: a study of the EORTC Melanoma Group*. Oral Presentation, EORTC Melanoma Group Meeting, Leeds, UK, October 2009.
- 2009 *Excellent long-term survival of patients with minimal sentinel node tumor burden (<0.1mm) according to the Rotterdam Criteria: a study of the EORTC Melanoma Group*. Oral Presentation, European Cancer Conference Organization (ECCO), Biannual Meeting, Berlin, Germany, September 2009.
- 2009 *Long-term Follow-up of Patients with Minimal Sentinel Node Tumor Burden According to the Rotterdam Criteria. A study of the EORTC Melanoma Group*. Oral Presentation. American Society of Clinical Oncology (ASCO), Annual Meeting, Orlando, Florida, USA, June 2009.
- 2009 *Molecular basis of IFN-sensitivity of ulcerated melanoma in the EORTC 18081 phase III trial comparing 2 yrs of Pegylated IFN to Observation as well as om archived material from EORTC 18952 and EORTC 18991 Trials*. Oral Presentation, EORTC Groups Annual Meeting (EGAM), Brussels, Belgium, March 2009.
- 2009 *MINITUB; Prospective Registration Study in Sentinel Node (SN) Positive Patients with Minimal SN Tumor Burden Managed without Complete Lymph Node Dissection (CLND)*, Oral Presentation, EORTC Groups Annual Meeting (EGAM), Brussels, Belgium, March 2009.
- 2009 *Long-term Follow-up of Patients with Minimal Sentinel Node Tumor Burden (<0.1mm) according to the Rotterdam Criteria*. Oral Presentation, EORTC Groups Annual Meeting (EGAM), Brussels, Belgium, March 2009.
- 2008 *The sentinel node: Rotterdam criteria of tumor load and prognostic false positivity*. Faculty, Perspectives in Melanoma Meeting XII, the Hague, the Netherlands, October 2008.
- 2008 *Minimal Sentinel Node (SN) Tumor Burden According to the Rotterdam Criteria is the most Important Prognostic Factor for Survival in Melanoma Patients. A Multicenter Study in 388 SN Positive Patients*. Oral Presentation, Annual meeting of the Dutch Surgical Society, Veldhoven, the Netherlands, May 2008.
- 2008 *Sentinel Node (SN) Tumor Burden and its Importance in Melanoma. Results of a Multicenter Study Conducted within the EORTC Melanoma Group Network*. Invited Speaker, Annual meeting of the the Polish Surgical Oncology Society, Bydgoszcz, Poland, May 2008.

- 2008 *Minimal Sentinel Node (SN) Tumor Burden According to the Rotterdam Criteria is the most Important Prognostic Factor for Survival in Melanoma Patients. A Multicenter Study in 388 SN Positive Patients.* Oral Presentation, International Sentinel Node Society Biannual Meeting, Sydney, Australia, February 2008.
- 2007 *Sentinel Node Tumor Burden According to the Rotterdam Criteria is the most Important Prognostic Factor for Survival in Melanoma Patients. A Multicenter Study in 388 SN Positive Patients.* Oral Presentation, Staff Research Day of the Department of Surgery of the Erasmus MC, Rotterdam, the Netherlands, December 2007.
- 2007 *Prognosis depends on Micro-Anatomic Patterns of Melanoma Micrometastases within the Sentinel Node (SN) – A Multicenter Study in 388 SN Positive Patients.* Oral Presentation, European Cancer Conference Organization (ECCO), Biannual Meeting, Barcelona, Spain, September 2007.
- 2007 *Biologic and Prognostic Aspects of Sentinel Node Tumor Load and Topography of Micrometastases.* Invited Speaker, Eurocancer 2007, Paris, France, June 2007.
- 2007 *The Current Status of the Sentinel Node Procedure for Melanoma Patients.* Invited Educational Lecture, Saint Elizabeth Hospital, Willemstad, Curacao, May 2007.
- 2007 *Ultrasound guided FNAC in Sentinel Nodes of Melanoma patients – Is a reduction in SN Procedures Possible?* Oral Presentation, Annual meeting of the Dutch Surgical Society, Veldhoven, the Netherlands, May 2007.
- 2006 *Sentinel node versus therapeutic lymph node dissection – a multivariate analysis.* Oral Presentation, Staff Research Day of the Department of Surgery of the Erasmus MC, Rotterdam, the Netherlands, December 2006.
- 2006 *Sentinel node versus therapeutic lymph node dissection – a multivariate analysis.* Oral Presentation, International Sentinel Node Society Biannual Meeting, Rome, Italy, November 2006.
- 2006 *Micro Anatomic Characteristics of Melanoma Metastases in the Sentinel Nod(s) (SN) Predict Survival and Question the Need for Complete Lymph Node Dissection (CLND)* Oral Presentation, International Sentinel Node Society Biannual Meeting, Rome, Italy, November 2006.
- 2006 *Micro Anatomic Characteristics of Melanoma Metastases in the Sentinel Nod(s) (SN) Predict Survival and Question the Need for Complete Lymph Node Dissection (CLND)* Oral Presentation. American Society of Clinical Oncology (ASCO), Annual Meeting, Atlanta, GA, USA, June 2006.
- 2006 *Micro Anatomic Characteristics of Melanoma Metastases in the Sentinel Nod(s) (SN) Predict Survival and Question the Need for Complete Lymph Node Dissection (CLND)* Oral Presentation, Annual meeting of the Dutch Surgical Society, Veldhoven, the Netherlands, May 2006.
- 2006 *Micro Anatomic Characteristics of Melanoma Metastases in the Sentinel Nod(s) (SN) Predict Survival and Question the Need for Complete Lymph Node Dissection (CLND)* Oral Presentation, EORTC Young Investigators meeting, Berlin, Germany, January 2006.
- 2005 *High Positive Sentinel Node Identification Rate by EORTC Melanoma Group Protocol – Prognostic Indicators of Metastatic Patterns after Sentinel Node Biopsy in Melanoma.*

- 2005 Oral Presentation, European Cancer Conference Organization (ECCO), Biannual Meeting, Paris, France, November 2005.  
*High Positive Sentinel Node Identification Rate by EORTC Melanoma Group Protocol – Prognostic Indicators of Metastatic Patterns after Sentinel Node Biopsy in Melanoma.*  
Oral Presentation, EORTC Melanoma Group Annual Meeting, Warsaw, Poland, September 2005.
- 2004 *Sentinel Node procedure for Melanoma patients.* Oral Presentation, Staff Research Day of the Department of Surgery of the Erasmus MC, Rotterdam, the Netherlands, December 2004.

#### Other

- 2006 Selected for U.S.A. Men's National Field Hockey Team
- 2003 Selected for U.S.A. Men's National Field Hockey Team
- 1999 Selected for U.S.A. U-21 National Field Hockey Team
- 1997 – 2006 Selected for numerous First Men's Club Premier Teams in the Dutch National Field Hockey League (Championship/League 1)

#### Referees

1. Prof. Georgina V. Long, AO, BSc (Hons1, UM) PhD MBBS (Hons) FRACP FAHMS  
Professor of Melanoma Medical Oncology and Translational Research, The University of Sydney  
Co-Medical Director of Melanoma Institute Australia  
Melanoma Institute Australia and Royal North Shore Hospital  
40 Rocklands Road, Wollstonecraft, North Sydney, NSW 2060, Australia  
Tel. +61 (0)2 9911 7336  
E-mail: [georgina.long@sydney.edu.au](mailto:georgina.long@sydney.edu.au)
2. Prof. Richard A. Scolyer, AO, BMedSci, MBBS, MD, FRCPA, FRCPath, FAHMS  
Clinical Professor, Sydney Medical School, The University of Sydney  
Co-Medical Director of Melanoma Institute Australia  
Department of Tissue Pathology & Diagnostic Oncology  
Royal Prince Alfred Hospital  
Missenden Road, Camperdown, Sydney, NSW 2050, Australia  
Tel. + 61 (0)2 9911 7336  
E-mail: [richard.scolyer@health.nsw.gov.au](mailto:richard.scolyer@health.nsw.gov.au)
3. Prof. Dr. Alexander M.M. Eggermont, MD, PhD  
Professor Immunotherapy University Medical Center Utrecht, the Netherlands  
Emeritus Professor Oncology, University Paris-Saclay, France  
Emeritus Professor Surgical Oncology, Erasmus University Rotterdam, the Netherlands  
Board of the Comprehensive Cancer Center Munich (CCCM), Technical University Munich, Ludwig Maximilliaan University Munich, Germany  
Chief Scientific Officer, Princess Maxima Center – Pediatric Oncology  
Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands  
Tel. +31 (0)88 972 72 72  
E-mail: [alexander.eggermont@prinsesmaximacentrum.nl](mailto:alexander.eggermont@prinsesmaximacentrum.nl)

4. Prof. Dr. Michel W.J.M. Wouters, MD, PhD  
Professor Quality of Cancer Care, Leiden University, the Netherlands  
Chair of the Division of Surgical Oncology, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, the Netherlands  
Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands  
Tel. +31 (0)20 512 91 11  
E-mail. [m.wouters@nki.nl](mailto:m.wouters@nki.nl)

#### Editorial Positions

From 2024	Current Problems in Surgery – Lead Editor for Surgical Oncology
From 2024	Surgical Oncology Insight – Editorial Board Member
From 2023	EJC Skin Cancer – Editorial Board Member
From 2023	ANZ J Surg – Specialty Editor for Surgical Oncology
2018 – 2021	Nederlandse Tijdschrift voor Oncologie (NTvO) – Editorial Board member
From 2017	European Journal of Cancer (EJC) – Editorial Board member for Clinical Oncology Section
From 2015	Annals of Surgical Oncology (ASO) – Editorial Board member for Melanoma Section

#### Peer Review

From 2023	Cancer Communications
From 2022	Nature Reviews Clinical Oncology
2022	Cancer Care Ontario – Guideline reviewer
From 2022	American Journal of Clinical Dermatology (AJCD)
From 2022	Australasian Journal of Plastic Surgery (AJOPS)
From 2022	Nature Medicine
From 2021	The Lancet
From 2021	Journal of The American College of Surgeons
From 2021	Expert Opinion On Investigational Drugs
From 2021	Therapeutic Advances in Medical Oncology
From 2021	Expert Opinion On Biological Therapy
From 2021	Cellular & Molecular Immunology
From 2020	Journal of ImmunoTherapy of Cancer (JITC)
From 2020	Immunotherapy
From 2018	Targeted Oncology
From 2012	Pharmacoeconomics & Outcomes Research
From 2011	Journal of Clinical Oncology (JCO)
From 2011	Journal of Plastic, Reconstructive & Aesthetic Surgery (JPRAS)
From 2011	Journal of the European Academy of Dermatology and Venereology (EADV)
From 2010	Cancer (Journal)
2010 – 2021	Dutch Journal of Medicine (Nederlands Tijdschrift voor Geneeskunde; NTvG)
From 2009	Annals of Surgical Oncology (ASO)
From 2009	Melanoma Research

From 2008     APMIS (Acta Pathologica, Microbiologica et Immunologica Scandinavica)  
 From 2007     European Journal of Cancer (EJC)  
 From 2006     European Journal of Surgical Oncology (EJSO)

### Book Contributions

- 2024           *Leerboek oncologie (in Dutch)*  
 11<sup>th</sup> edition  
 Chapter 24 : “Huidtumoren” R. van Doorn, **ACJ van Akkooi**, R van Dijk, J.B.A.G.  
 Haanen
- 2021           *Leerboek chirurgie (in Dutch)*  
 Editor: Prof. Dr. E. Heineman, Dr. D.J. Heineman, Dr. J.F.M. Lange jr.,  
 Prof. Dr. J.D. Blankensteijn, Prof. Dr. M.A. Boermeester, Prof. Dr. I.H.M. Borel Rinkes,  
 Prof. Dr. J.M. Klaase, Prof. Dr. I.B. Schipper, Dr. W.H. Schreurs, Prof. Dr. R.M.H. Wijnen  
 Published by: Bohn, Stafleu & van Loghum  
 Chapter 36 : “Melanoom en andere huidtumoren”, **ACJ van Akkooi**, LB Been  
 ISBN 978-90-368-2517-7
- 2021           *‘Een melanoom daar schrik ik van!’ (in Dutch)*  
 1st edition  
 Editor: Zij van boven  
 Published by: Poiesz Uitgevers bv, Koog aan de Zaan  
 ISBN: 978-94-94549-939
- 2020           *Leerboek oncologie (in Dutch)*  
 10<sup>th</sup> edition  
 Editor: J.H.J.M. van Krieken, R.G.H. Beets-Tan, A.J. Gelderblom, M.J.J. Olofsen, H.J.T.  
 Rutten.  
 Published by Bohn, Stafleu & van Loghum  
 Chapter 24 : “Huidtumoren” R. van Doorn, **ACJ van Akkooi**, R van Dijk, J.B.A.G.  
 Haanen  
 ISBN 978-90-368-2448-4 & 978-90-368-2449-1 (eBook)
- 2018           *Locoregional Tumor Therapy.*  
 Editor: Eric Van Cutsem, Thomas J. Vogl, Franco Orsi, Alberto Sobrero.  
 Published by Springer. ISBN 978-3-319-69946-2 & 978-3-319-69947-9 (eBook)  
 Chapter: *Melanoma.* **van Akkooi ACJ.**
- 2018           *Malignancies of the Groin. Considerations and Anatomic Considerations.* Editors:  
 Keath A. Delman & Viraj A. Master. Published by Springer Nature. ISBN 978-3-319-  
 60857-0 & 978-3-319-60858-7 (eBook)  
 Chapter 6: *Surgical and Anatomic Considerations of Malignancies Affecting the Groin:*  
*Considerations for Melanoma.* **van Akkooi, ACJ.**

### Publication Metrics (as of 12.06.2024)

Number of Pubmed Peer Reviewed Publications	249
Number of Citations	10.576

Scopus H-index	43
Highest Journal Impact Factor (JIF)	The Lancet (JIF 168.9)
Highest Number of Citations	1322; Adjuvant pembrolizumab versus placebo in stage III melanoma, N Engl J Med. 2018.
First author (excluding shared)	12 (7%)
Senior author (excluding shared)	52 (30%)
Single author	5 (3%)
Top Citation Percentiles	25.1% in top 10% most cited publications
Top Journal Percentiles	58.2% in top 10% journals by CiteScore

#### PubMed Listed Peer Reviewed Publications

1. Novis E, **van Akkooi ACJ**. *Management of Localized Melanoma in the Anti-PD-1 Era*. Curr Oncol Rep. 2024 Jun 6. doi: 10.1007/s11912-024-01556-z. Epub ahead of print. PMID: 38842606.
2. Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, Hoeijmakers LL, Saw RPM, Lijnsvelt JM, Maher NG, Pulleman SM, Gonzalez M, Torres Acosta A, van Houdt WJ, Lo SN, Kuijpers AMJ, Spillane A, Klop WMC, Pennington TE, Zuur CL, Shannon KF, Seinstra BA, Rawson RV, Haanen JBAG, Ch'ng S, Naipal KAT, Stretch J, van Thienen JV, Rtshiladze MA, Wilgenhof S, Kapoor R, Meerveld-Eggink A, Grijpink-Ongering LG, **van Akkooi ACJ**, Reijers ILM, Gyorki DE, Grünhagen DJ, Speetjens FM, Vliek SB, Placzke J, Spain L, Stassen RC, Amini-Adle M, Lebbé C, Faries MB, Robert C, Ascierto PA, van Rijn R, van den Berkmortel FWPJ, Piersma D, van der Westhuizen A, Vreugdenhil G, Aarts MJB, Stevense-den Boer MAM, Atkinson V, Khatkhat M, Andrews MC, van den Eertwegh AJM, Boers-Sonderen MJ, Hospers GAP, Carlino MS, de Groot JB, Kapiteijn E, Suijkerbuijk KPM, Rutkowski P, Sandhu S, van der Veldt AAM, Long GV. *Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma*. N Engl J Med. 2024 Jun 2. doi: 10.1056/NEJMoa2402604. Epub ahead of print. PMID: 38828984.
3. Lugowska I, Becker JC, Ascierto PA, Veness M, Blom A, Lebbe C, Migliano E, Hamming-Vrieze O, Goebeler M, Kneitz H, Nathan P, Rutkowski P, Slowinska M, Schadendorf D, Piulats JM, Petrelli F, **van Akkooi ACJ**, Berruti A; ESMO Guidelines Committee. *Merkel-cell carcinoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up*. ESMO Open. 2024 May;9(5):102977. doi: 10.1016/j.esmoop.2024.102977. Epub 2024 Apr 30. PMID: 38796285; PMCID: PMC11145756.
4. Zijlker LP, Chen H, Spillane AJ, Gonzalez M, Pennington TE, Menzies AM, Lo SN, Ferguson P, Rawson R, Colebatch AJ, Stretch JR, Thompson JF, Ch'ng S, Nieweg O, Shannon KF, Long GV, Scolyer RA, Saw RPM, **van Akkooi ACJ**. *The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort*. Ann Surg Oncol. 2024 May 18. doi: 10.1245/s10434-024-15274-0. Epub ahead of print. PMID: 38762644.
5. Zijlker LP, Chen H, Spillane AJ, Gonzalez M, Pennington TE, Menzies AM, Lo SN, Ferguson P, Rawson R, Colebatch AJ, Stretch JR, Thompson JF, Ch'ng S, Nieweg O, Shannon KF, Long GV, Scolyer RA, Saw RPM, **van Akkooi ACJ**. *ASO Visual*



*Abstract: The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma: An Australian Cohort.* Ann Surg Oncol. 2024 May 17. doi: 10.1245/s10434-024-15348-z. Epub ahead of print. PMID: 38758487.

6. Versluis JM, Blankenstein SA, Dimitriadis P, Wilmott JS, Elens R, Blokx WAM, van Houdt W, Menzies AM, Schrage YM, Wouters MWJM, Sanders J, Broeks A, Scolyer RA, Suijkerbuijk KPM, Long GV, **Akkooi ACJV**, Blank CU. *Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.* J Immunother Cancer. 2024 Apr 27;12(4):e008125. doi: 10.1136/jitc-2023-008125. PMID: 38677880; PMCID: PMC11057279.
7. Kuijpers AMJ, **van Akkooi ACJ**. *Neo-Adjuvant Therapy for Metastatic Melanoma.* Cancers (Basel). 2024 Mar 22;16(7):1247. doi: 10.3390/cancers16071247. PMID: 38610925; PMCID: PMC11010858.
8. Stassen RC, Maas CCHM, van der Veldt AAM, Lo SN, Saw RPM, Varey AHR, Scolyer RA, Long GV, Thompson JF, Rutkowski P, Keilholz U, **van Akkooi ACJ**, Verhoef C, van Klaveren D, Grünhagen DJ. *Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis.* Lancet Oncol. 2024 Apr;25(4):509-517. doi: 10.1016/S1470-2045(24)00076-7. PMID: 38547894.
9. Holmberg CJ, Zijlker LP, Katsarelis D, Huibers AE, Wouters MWJM, Schrage Y, Reijers SJM, van Thienen JV, Grünhagen DJ, Martner A, Nilsson JA, **van Akkooi ACJ**, Ny L, van Houdt WJ, Bagge RO. *The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial).* Eur J Surg Oncol. 2024 Mar 12;50(6):108265. doi: 10.1016/j.ejso.2024.108265. Epub ahead of print. PMID: 38493679.
10. Kennedy OJ, Glasse N, Kicinski M, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Giacomo AMD, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, **van Akkooi ACJ**, Gandini S, Buhner E, Suci S, Robert C, Eggermont AMM, Mandala M, Lorigan P, Valpione S. *Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.* Eur J Cancer. 2024 Apr;201:113585. doi: 10.1016/j.ejca.2024.113585. Epub 2024 Feb 1. PMID: 38402687.
11. Laeijendecker AE, El Sharouni MA, Stathonikos N, Spoto CPE, van de Wiel BA, Eijken EJE, Mulder M, Mooyaart AL, Szumera-Cieckiewicz A, Mihic-Probst D, Massi D, Cook M, Koljenovic S, Alos L, van Diest PJ, **van Akkooi ACJ**, Blokx W. *The difficulty with measuring the largest melanoma tumour diameter in sentinel lymph nodes.* J Clin Pathol. 2024 Feb 20:jcp-2023-209354. doi: 10.1136/jcp-2023-209354. Epub ahead of print. PMID: 38378246.
12. Egeler M, Lai-Kwon J, Tissier R, Fraterman I, Kuijpers A, Van Houdt W, Wilgenhof S, Rao A, Sandhu S, Lee R, Eriksson H, van Leeuwen M, de Ligt K, **van Akkooi A**, van de Poll-Franse L. *Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy.* Eur J Cancer. 2024 Mar;200:113601. doi: 10.1016/j.ejca.2024.113601. Epub 2024 Feb 4. PMID: 38340383.



13. Varey AHR, Li I, El Sharouni MA, Simon J, Dedeilia A, Ch'ng S, Saw RPM, Spillane AJ, Shannon KF, Pennington TE, Rtshiladze M, Stretch JR, Nieweg OE, **van Akkooi A**, Sullivan RJ, Boland GM, Gershenwald JE, van Diest PJ, Scolyer RA, Long GV, Thompson JF, Lo SN. *Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator*. J Clin Oncol. 2024 Feb 5;JCO2301020. doi: 10.1200/JCO.23.01020. Epub ahead of print. PMID: 38315961.
14. Olofsson Bagge R, Mikiver R, Marchetti MA, Lo SN, **van Akkooi ACJ**, Coit DG, Ingvar C, Isaksson K, Scolyer RA, Thompson JF, Varey AHR, Wong SL, Lyth J, Bartlett EK. *Population-Based Validation of the MIA and MSKCC Tools for Predicting Sentinel Lymph Node Status*. JAMA Surg. 2024 Mar 1;159(3):260-268. doi: 10.1001/jamasurg.2023.6904. Erratum in: JAMA Surg. 2024 Mar 1;159(3):353. PMID: 38198163; PMCID: PMC10782377.
15. Gjorup CA, **van Akkooi ACJ**. ASO Author Reflections: *Recurrence in Sentinel Node-Positive Node Fields in Melanoma Patients Undergoing Surveillance Is More Common outside the Node Field*. Ann Surg Oncol. 2024 Mar;31(3):1880-1881. doi: 10.1245/s10434-023-14623-9. Epub 2023 Dec 4. PMID: 38044350.
16. Stahlie EHA, Zijlker LP, Wouters MWJM, Schrage YM, van Houdt WJ, **van Akkooi ACJ**. *Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma*. Melanoma Res. 2024 Feb 1;34(1):63-69. doi: 10.1097/CMR.0000000000000946. Epub 2023 Nov 28. PMID: 38016153.
17. Gjorup CA, Woodford R, Li I, Carlino MS, Ch'ng S, Chung D, Hsiao E, Lo SN, London K, Long GV, Menzies AM, Nieweg OE, Pennington TE, Rtshiladze MA, Saw RPM, Scolyer RA, Shannon KF, Spillane AJ, Stretch JR, Thompson JF, Varey AHR, **van Akkooi ACJ**. *Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging*. Ann Surg Oncol. 2024 Mar;31(3):1857-1864. doi: 10.1245/s10434-023-14526-9. Epub 2023 Nov 15. PMID: 37966706; PMCID: PMC10838221.
18. **van Akkooi ACJ**. *Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?* Ann Surg Oncol. 2024 Jan;31(1):1-3. doi: 10.1245/s10434-023-14416-0. Epub 2023 Oct 16. PMID: 37843663.
19. Zijlker LP, Levy S, Wolters W, van Thienen JV, **van Akkooi ACJ**, Tesselaar MET. *Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET/CT-confirmed complete response*. Cancer. 2024 Feb 1;130(3):433-438. doi: 10.1002/cncr.35050. Epub 2023 Oct 3. PMID: 37788133.
20. Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, **van Akkooi A**, Bataille V, Bastholt L, Dreno B, Dummer R, Fargnoli MC, Forsea AM, Harwood CA, Hauschild A, Hoeller C, Kandolf-Sekulovic L, Kaufmann R, Kelleners-Smeets NW, Lallas A, Leiter U, Malvey J, Del Marmol V, Moreno-Ramirez D, Pellacani G, Peris K, Saiag P, Tagliaferri L, Trakatelli M, Ioannides D, Vieira R, Zalaudek I, Arenberger P, Eggermont AMM, Röcken M, Grob JJ, Lorigan P; EADO, EDF, ESTRO, UEMS, EADV and EORTC. *European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023*. Eur J Cancer. 2023 Nov;193:113251. doi: 10.1016/j.ejca.2023.113251. Epub 2023 Jul 28. PMID: 37717283.

21. Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, **van Akkooi A**, Bataille V, Bastholt L, Dreno B, Dummer R, Fargnoli MC, Forsea AM, Harwood CA, Hauschild A, Hoeller C, Kandolf-Sekulovic L, Kaufmann R, Kelleners-Smeets NW, Lallas A, Leiter U, Malvey J, Del Marmol V, Moreno-Ramirez D, Pellacani G, Peris K, Saiag P, Tagliaferri L, Trakatelli M, Ioannides D, Vieira R, Zalaudek I, Arenberger P, Eggermont AMM, Röcken M, Grob JJ, Lorigan P; EADO, EDF, ESTRO, UEMS, EADV and EORTC. *European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023*. Eur J Cancer. 2023 Nov;193:113252. doi: 10.1016/j.ejca.2023.113252. Epub 2023 Jul 28. PMID: 37708630.
22. **van Akkooi AC**, Hauschild A, Long GV, Mandala M, Kicinski M, Govaerts AS, Klauk I, Ouali M, Lorigan PC, Eggermont AM. *COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma*. Future Oncol. 2023 Sep;19(30):2017-2027. doi: 10.2217/fon-2023-0414. Epub 2023 Sep 4. PMID: 37665297.
23. Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, Bollin K, Chacon M, Davis N, Faries MB, Funchain P, Gold JS, Guild S, Gyorki DE, Kaur V, Khushalani NI, Kirkwood JM, McQuade JL, Meyers MO, Provenzano A, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrer G, Swami U, Truong TG, Tsai KK, **van Akkooi A**, Weber J. *Systemic Therapy for Melanoma: ASCO Guideline Update*. J Clin Oncol. 2023 Oct 20;41(30):4794-4820. doi: 10.1200/JCO.23.01136. Epub 2023 Aug 14. PMID: 37579248.
24. Becker JC, Ugurel S, Leiter U, Meier F, Gutzmer R, Haferkamp S, Zimmer L, Livingstone E, Eigentler TK, Hauschild A, Kiecker F, Hassel JC, Mohr P, Fluck M, Thomas I, Garzarolli M, Grimmelmann I, Drexler K, Spillner AN, Eckhardt S, Schadendorf D; DeCOG (**van Akkooi as part of DeCOG**). *Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial*. Lancet. 2023 Sep 2;402(10404):798-808. doi: 10.1016/S0140-6736(23)00769-9. Epub 2023 Jul 11. Erratum in: Lancet. 2023 Oct 21;402(10411):1422. PMID: 37451295.
25. Lee R, Mandala M, Long GV, Eggermont AMM, **van Akkooi ACJ**, Sandhu S, Garbe C, Lorigan P. *Adjuvant therapy for stage II melanoma: the need for further studies*. Eur J Cancer. 2023 Aug;189:112914. doi: 10.1016/j.ejca.2023.05.003. Epub 2023 May 8. PMID: 37301717.
26. Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suci S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, **van Akkooi ACJ**, Robert C, Eggermont AMM, Lorigan P, Mandala M. *Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma*. Eur J Cancer. 2023 Aug;189:112900. doi: 10.1016/j.ejca.2023.04.016. Epub 2023 Apr 29. PMID: 37277264.
27. Thompson JF, Hynstrom J, Caracò C, Zager JS, Jahkola T, Bowles TL, Pennacchioli E, Hoekstra HJ, Moncrieff M, Ingvar C, **van Akkooi A**, Sabel MS, Levine EA, Henderson M, Dummer R, Rossi CR, Kane JM 3rd, Trocha S, Wright F, Byrd DR, Matter M, MacKenzie-Ross A, Kelley MC, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, O'Donoghue C, Sardi A, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Testori AAE, Scolyer RA, Elashoff DE, Cochran AJ, Faries MB. *Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive*

- Sentinel Node Melanoma*. Ann Surg Oncol. 2023 Jul;30(7):4359-4360. doi: 10.1245/s10434-023-13570-9. Epub 2023 May 6. PMID: 37149545.
28. Hoefsmit EP, Völlmy F, Rozeman EA, Reijers ILM, Versluis JM, Hoekman L, **van Akkooi ACJ**, Long GV, Schadendorf D, Dummer R, Altelaar M, Blank CU. *Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence*. Cancer Res Commun. 2023 Apr 20;3(4):672-683. doi: 10.1158/2767-9764.CRC-23-0015. PMID: 37089863; PMCID: PMC10117404.
29. Huis In 't Veld EA, Boere T, Zuur CL, Wouters MW, **van Akkooi ACJ**, Haanen JBAG, Crijns MB, Smith MJ, Mooyaart A, Wakkee M, Sewnaik A, Strauss DC, Grunhagen DJ, Verhoef C, Hayes AJ, van Houdt WJ. *Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma*. Ann Surg Oncol. 2023 Aug;30(8):5017-5026. doi: 10.1245/s10434-023-13306-9. Epub 2023 Mar 29. PMID: 36991168; PMCID: PMC10319664.
30. Zijlker LP, van der Burg SJC, Blank CU, Zuur CL, Klop WMC, Wouters MWMJ, van Houdt WJ, **van Akkooi ACJ**. *Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery*. Eur J Cancer. 2023 May;185:131-138. doi: 10.1016/j.ejca.2023.03.003. Epub 2023 Mar 7. PMID: 36989829.
31. Reijers ILM, Rao D, Versluis JM, Menzies AM, Dimitriadis P, Wouters MW, Spillane AJ, Klop WMC, Broeks A, Bosch LJW, Lopez-Yurda M, van Houdt WJ, Rawson RV, Grijpink-Ongering LG, Gonzalez M, Cornelissen S, Bouwman J, Sanders J, Plasmeijer E, Elshot YS, Scolyer RA, van de Wiel BA, Peeper DS, **van Akkooi ACJ**, Long GV, Blank CU. *IFN- $\gamma$  signature enables selection of neoadjuvant treatment in patients with stage III melanoma*. J Exp Med. 2023 May 1;220(5):e20221952. doi: 10.1084/jem.20221952. Epub 2023 Mar 15. PMID: 36920329; PMCID: PMC10037109.
32. Boshuizen J, Vredevoogd DW, Krijgsman O, Ligtenberg MA, Blankenstein S, de Bruijn B, Frederick DT, Kenski JCN, Parren M, Brüggemann M, Madu MF, Rozeman EA, Song JY, Horlings HM, Blank CU, **van Akkooi ACJ**, Flaherty KT, Boland GM, Peeper DS. *Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance*. Nat Commun. 2023 Feb 7;14(1):672. doi: 10.1038/s41467-023-35852-2. Erratum for: Nat Commun. 2020 Aug 7;11(1):3946. PMID: 36750559; PMCID: PMC9905532.
33. **van Akkooi ACJ**, Blank C, Eggermont AMM. *Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma*. Eur J Cancer. 2023 Mar;182:38-42. doi: 10.1016/j.ejca.2023.01.004. Epub 2023 Jan 11. PMID: 36738540.
34. Egeler MD, van Leeuwen M, Fraterman I, van den Heuvel NMJ, Boekhout AH, Lai-Kwon J, Wilthagen EA, Eriksson H, Haanen JB, Wilgenhof S, Ascierto PA, **van Akkooi ACJ**, van de Poll-Franse LV. *Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review*. Crit Rev Oncol Hematol. 2023 Mar;183:103919. doi: 10.1016/j.critrevonc.2023.103919. Epub 2023 Feb 1. PMID: 36736511.
35. **van Akkooi ACJ**, Schadendorf D, Eggermont AMM. *Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma*. Eur J Cancer. 2023 Mar;182:163-169. doi: 10.1016/j.ejca.2022.12.022. Epub 2022 Dec 29. PMID: 36681612.

36. Versluis JM, Menzies AM, Sikorska K, Rozeman EA, Saw RPM, van Houdt WJ, Eriksson H, Klop WMC, Ch'ng S, van Thienen JV, Mallo H, Gonzalez M, Torres Acosta A, Griepink-Ongering LG, van der Wal A, Bruining A, van de Wiel BA, Scolyer RA, Haanen JBAG, Schumacher TN, **van Akkooi ACJ**, Long GV, Blank CU. *Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials*. *Ann Oncol*. 2023 Apr;34(4):420-430. doi: 10.1016/j.annonc.2023.01.004. Epub 2023 Jan 18. PMID: 36681299.
37. Zijlker LP, Bakker M, van der Hiel B, Bruining A, Klop WMC, Zuur CL, Wouters MWJM, **van Akkooi ACJ**. *Baseline ultrasound and FDG-PET/CT imaging in Merkel cell carcinoma*. *J Surg Oncol*. 2023 Apr;127(5):841-847. doi: 10.1002/jso.27193. Epub 2022 Dec 27. PMID: 36573839.
38. Zager JS, **van Akkooi ACJ**. *Talimogene Laherparepvec in Combination with Immunotherapy, A Viable Option?* *Ann Surg Oncol*. 2023 Mar;30(3):1279-1281. doi: 10.1245/s10434-022-12940-z. Epub 2022 Dec 15. PMID: 36520235.
39. Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, Geukes Foppen MH, Stoltenberg Granhøj J, Nuijen B, Nijenhuis C, Jedema I, van Zon M, Scheij S, Beijnen JH, Hansen M, Voermans C, Noringriis IM, Monberg TJ, Holmstroem RB, Wever LDV, van Dijk M, Griepink-Ongering LG, Valkenet LHM, Torres Acosta A, Karger M, Borgers JSW, Ten Ham RMT, Retèl VP, van Harten WH, Lalezari F, van Tinteren H, van der Veldt AAM, Hospers GAP, Stevense-den Boer MAM, Suijkerbuijk KPM, Aarts MJB, Piersma D, van den Eertwegh AJM, de Groot JB, Vreugdenhil G, Kapiteijn E, Boers-Sonderen MJ, Fiets WE, van den Berkmortel FWPI, Ellebaek E, Hölmich LR, **van Akkooi ACJ**, van Houdt WJ, Wouters MWJM, van Thienen JV, Blank CU, Meerveld-Eggink A, Klobuch S, Wilgenhof S, Schumacher TN, Donia M, Svane IM, Haanen JBAG. *Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma*. *N Engl J Med*. 2022 Dec 8;387(23):2113-2125. doi: 10.1056/NEJMoa2210233. PMID: 36477031.
40. Franke V, Stahlie EHA, Klop WMC, Zuur CL, Berger DMS, van der Hiel B, van de Wiel BA, Wouters MWJM, van Houdt WJ, **van Akkooi ACJ**. *Talimogene laherparepvec monotherapy for head and neck melanoma patients*. *Melanoma Res*. 2023 Feb 1;33(1):66-70. doi: 10.1097/CMR.0000000000000866. Epub 2022 Nov 29. PMID: 36454284.
41. Zijlker LP, Eggermont AMM, **van Akkooi ACJ**. *The end of wide local excision (WLE) margins for melanoma ?* *Eur J Cancer*. 2023 Jan;178:82-87. doi: 10.1016/j.ejca.2022.10.028. Epub 2022 Nov 2. PMID: 36423526.
42. Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, **van Akkooi ACJ**, Lorigan P, Grebennik D, Krepler C, Marreaud S, Suci S, Robert C. *Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma*. *NEJM Evid*. 2022 Nov;1(11):EVIDoa2200214. doi: 10.1056/EVIDoa2200214. Epub 2022 Sep 10. PMID: 38319852.
43. Blankenstein SA, Bonenkamp JJ, Aarts MJB, van den Berkmortel FWPI, Blank CU, Blokx WAM, Boers-Sonderen MJ, van den Eertwegh AJM, Franken MG, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn EW, van Not OJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, van der Veldt AAM, Vreugdenhil G, Westgeest HM, Wouters MWJM, **van Akkooi ACJ**. *Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?* *Ann Surg Oncol*. 2023 Jan;30(1):573-586. doi: 10.1245/s10434-022-12600-2. Epub 2022 Oct 6. PMID: 36203067.

44. Eroglu Z, Broman KK, Thompson JF, Nijhuis A, Hieken TJ, Kottschade L, Farma JM, Hotz M, Deneve J, Fleming M, Bartlett EK, Sharma A, Dossett L, Hughes T, Gyorki DE, Downs J, Karakousis G, Song Y, Lee A, Berman RS, **van Akkooi A**, Stahlie E, Han D, Vetto J, Beasley G, Farrow NE, Hui JYC, Moncrieff M, Nobes J, Baecher K, Perez M, Lowe M, Ollila DW, Collichio FA, Bagge RO, Mattsson J, Kroon HM, Chai H, Teras J, Sun J, Carr MJ, Tandon A, Babacan NA, Kim Y, Naqvi M, Zager J, Khushalani NI. *Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection*. *J Immunother Cancer*. 2022 Aug;10(8):e004417. doi: 10.1136/jitc-2021-004417. PMID: 36002183; PMCID: PMC9413295.
45. Rohaan MW, Stahlie EHA, Franke V, Zijlker LP, Wilgenhof S, van der Noort V, **van Akkooi ACJ**, Haanen JBAG. *Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial*. *BMC Cancer*. 2022 Aug 4;22(1):851. doi: 10.1186/s12885-022-09896-4. PMID: 35927710; PMCID: PMC9351098.
46. Multicenter Selective Lymphadenectomy Trials Study Group; Crystal JS, Thompson JF, Hyingstrom J, Caracò C, Zager JS, Jahkola T, Bowles TL, Pennacchioli E, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, **van Akkooi A**, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Neves RI, Rossi CR, Kane JM 3rd, Trocha S, Wright F, Byrd DR, Matter M, Hsueh EC, MacKenzie-Ross A, Kelley M, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Ariyan CE, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, McMasters KM, O'Donoghue C, van der Westhuizen A, Sardi A, Barth R, Barone R, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Molina M, Testori AAE, Foshag LJ, Van Kreuningen L, Wang HJ, Sim MS, Scolyer RA, Elashoff DE, Cochran AJ, Faries MB. *Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial*. *JAMA Surg*. 2022 Sep 1;157(9):835-842. doi: 10.1001/jamasurg.2022.2055. Erratum in: *JAMA Surg*. 2022 Sep 1;157(9):859. PMID: 35921122; PMCID: PMC9475390.
47. Stahlie EHA, **van Akkooi ACJ**, Plasmeijer E. *Dermoscopy as response evaluation tool for cutaneous malignant melanoma metastases treated with Talimogene Laherparepvec: a prospective feasibility study*. *J Eur Acad Dermatol Venereol*. 2022 Dec;36(12):2373-2378. doi: 10.1111/jdv.18479. Epub 2022 Aug 13. PMID: 35920755.
48. Gauci ML, Aristei C, Becker JC, Blom A, Bataille V, Dreno B, Del Marmol V, Forsea AM, Fargnoli MC, Grob JJ, Gomes F, Hauschild A, Hoeller C, Harwood C, Kelleners-Smeets N, Kaufmann R, Lallas A, Malveyh J, Moreno-Ramirez D, Peris K, Pellacani G, Saiag P, Stratigos AJ, Vieira R, Zalaudek I, **van Akkooi ACJ**, Lorigan P, Garbe C, Lebbé C; *European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC)*. *Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022*. *Eur J Cancer*. 2022 Aug;171:203-231. doi: 10.1016/j.ejca.2022.03.043. Epub 2022 Jun 19. PMID: 35732101.
49. Walker RJB, Look Hong NJ, Moncrieff M, **van Akkooi ACJ**, Jost E, Nessim C, van Houdt WJ, Stahlie EHA, Seo C, Quan ML, McKinnon JG, Wright FC, Mavros MN. *Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma: An International Multi-institutional Collaboration*. *Ann Surg Oncol*. 2022 Oct;29(11):7010-7017. doi: 10.1245/s10434-022-11936-z. Epub 2022 Jun 8. PMID: 35676603.



50. Reijers ILM, Menzies AM, **van Akkooi ACJ**, Versluis JM, van den Heuvel NMJ, Saw RPM, Pennington TE, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Hospers GAP, Rozeman EA, Klop WMC, van Houdt WJ, Sikorska K, van der Hage JA, Grünhagen DJ, Wouters MW, Witkamp AJ, Zuur CL, Lijnsvelt JM, Torres Acosta A, Griepink-Ongering LG, Gonzalez M, Józwiak K, Bierman C, Shannon KF, Ch'ng S, Colebatch AJ, Spillane AJ, Haanen JBAG, Rawson RV, van de Wiel BA, van de Poll- Franse LV, Scolyer RA, Boekhout AH, Long GV, Blank CU. *Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial*. Nat Med. 2022 Jun;28(6):1178-1188. doi: 10.1038/s41591-022-01851-x. Epub 2022 Jun 5. PMID: 35661157.
51. Holmberg CJ, Ny L, Hieken TJ, Block MS, Carr MJ, Sondak VK, Örténwall C, Katsarelis D, Dimitriou F, Menzies AM, Saw RP, Rogiers A, Straker RJ 3rd, Karakousis G, Applewaite R, Pallan L, Han D, Vetto JT, Gyorki DE, Tie EN, Vitale MG, Ascierto PA, Dummer R, Cohen J, Hui JY, Schachter J, Asher N, Helgadottir H, Chai H, Kroon H, Coventry B, Rothermel LD, Sun J, Carlino MS, Duncan Z, Broman K, Weber J, Lee AY, Berman RS, Teras J, Ollila DW, Long GV, Zager JS, **van Akkooi A**, Olofsson Bagge R. *The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study*. Eur J Cancer. 2022 Jul;169:210-222. doi: 10.1016/j.ejca.2022.03.041. Epub 2022 May 26. PMID: 35644725.
52. Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguín N, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Forsea AM, Grob JJ, Hoeller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Lytvynenko B, Malvey J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, **Van Akkooi ACJ**, Vieira R, Zalaudek I, Lorigan P; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). *European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022*. Eur J Cancer. 2022 Jul;170:256-284. doi: 10.1016/j.ejca.2022.04.018. Epub 2022 May 24. PMID: 35623961.
53. Franke V, Stahlie EHA, van der Hiel B, van de Wiel BA, Wouters MWJM, van Houdt WJ, **van Akkooi ACJ**. *Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective*. J Immunother. 2022 Jul-Aug 01;45(6):263-266. doi: 10.1097/CJI.0000000000000423. Epub 2022 May 18. PMID: 35580326.
54. Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguín N, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Forsea AM, Grob JJ, Höller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Lytvynenko B, Malvey J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, **Van Akkooi ACJ**, Vieira R, Zalaudek I, Lorigan P; *European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022*. Eur J Cancer. 2022 Jul;170:236-255. doi: 10.1016/j.ejca.2022.03.008. Epub 2022 May 12. PMID: 35570085.
55. Stahlie EHA, Mulder EEAP, Reijers S, Balduzzi S, Zuur CL, Klop WMC, van der Hiel B, Van de Wiel BA, Wouters MWJM, Schrage YM, van Houdt WJ, Grünhagen DJ, **van Akkooi ACJ**. *Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis*. Crit Rev Oncol Hematol. 2022 Jul;175:103705. doi: 10.1016/j.critrevonc.2022.103705. Epub 2022 May 13. PMID: 35569723.
56. van der Hiel B, Blankenstein SA, Aalbersberg EA, Wondergem M, Stokkel MPM, van de Wiel BA, Klop WMC, **van Akkooi ACJ**, Haanen JB. *18F-FDG PET/CT During Neoadjuvant Targeted Therapy*

*in Prior Unresectable Stage III Melanoma Patients: Can (Early) Metabolic Imaging Predict Histopathologic Response or Recurrence?* Clin Nucl Med. 2022 Jul 1;47(7):583-589. doi: 10.1097/RLU.0000000000004217. Epub 2022 Apr 22. PMID: 35452004.

57. **van Akkooi ACJ**, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Bagge RO, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI; *International Neoadjuvant Melanoma Consortium (INMC)*. *Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)*. Ann Surg Oncol. 2022 Aug;29(8):5241-5242. doi: 10.1245/s10434-022-11622-0. Erratum for: Ann Surg Oncol. 2022 Jun;29(6):3694-3708. PMID: 35426590.
58. **van Akkooi ACJ**, Zijlker LP, Wouters MWJM. *Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing*. BioDrugs. 2022 May;36(3):373-380. doi: 10.1007/s40259-022-00525-x. Epub 2022 Apr 9. PMID: 35397089; PMCID: PMC9148869.
59. Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khatkhat A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, **van Akkooi ACJ**, Robert C, Eggermont AMM, Lorigan P, Mandala M. *Prognostic and predictive value of  $\beta$ -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma*. Eur J Cancer. 2022 Apr;165:97-112. doi: 10.1016/j.ejca.2022.01.017. Epub 2022 Feb 24. PMID: 35220182.
60. Uitentuis SE, Bambach C, Elshot YS, Limpens J, **van Akkooi ACJ**, Bekkenk MW. *Merkel Cell Carcinoma, the Impact of Clinical Excision Margins and Mohs Micrographic Surgery on Recurrence and Survival: A Systematic Review*. Dermatol Surg. 2022 Apr 1;48(4):387-394. doi: 10.1097/DSS.0000000000003402. PMID: 35165221.
61. Davies EJ, Reijers SJM, **Van Akkooi ACJ**, Van Houdt WJ, Hayes AJ. *Isolated limb perfusion for locally advanced melanoma in the immunotherapy era*. Eur J Surg Oncol. 2022 Jun;48(6):1288-1292. doi: 10.1016/j.ejso.2022.01.027. Epub 2022 Feb 2. PMID: 35153102.
62. Reijers ILM, Rawson RV, Colebatch AJ, Rozeman EA, Menzies AM, **van Akkooi ACJ**, Shannon KF, Wouters MW, Saw RPM, van Houdt WJ, Zuur CL, Nieweg OE, Ch'ng S, Klop WMC, Spillane AJ, Long GV, Scolyer RA, van de Wiel BA, Blank CU. *Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma*. JAMA Surg. 2022 Apr 1;157(4):335-342. doi: 10.1001/jamasurg.2021.7554. PMID: 35138335; PMCID: PMC8829746.
63. Zijlker LP, **van Akkooi ACJ**. *Stage III melanoma: role of lymph node dissection and (neo-)adjuvant systemic therapies*. Br J Surg. 2022 Apr 19;109(5):397-398. doi: 10.1093/bjs/znac019. PMID: 35136944.
64. Broman KK, Hughes TM, Bredbeck BC, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, **van Akkooi A**, Ollila



- DW, O'shea K, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Hotz M, Farma JM, Deneve JL, Fleming MD, Perez M, Baecher K, Lowe M, Bagge RO, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley GM, Hui JYC, Been L, Kruijff S, Sinco B, Sarnaik AA, Sondak VK, Zager JS, Dossett LA; *International High Risk Melanoma Consortium. International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers*. *Ann Surg*. 2023 May 1;277(5):e1106-e1115. doi: 10.1097/SLA.0000000000005370. Epub 2023 Apr 6. PMID: 35129464; PMCID: PMC10097464.
65. **van Akkooi ACJ**, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Olofsson Bagge R, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI; International Neoadjuvant Melanoma Consortium (INMC). *Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)*. *Ann Surg Oncol*. 2022 Jun;29(6):3694-3708. doi: 10.1245/s10434-021-11236-y. Epub 2022 Jan 28. Erratum in: *Ann Surg Oncol*. 2022 Apr 15;: PMID: 35089452.
66. Stahlie EHA, **van Akkooi ACJ**. *ASO Author Reflections: Validation of Prediction Model for Response to Treatment with T-VEC*. *Ann Surg Oncol*. 2022 Mar;29(3):1645-1646. doi: 10.1245/s10434-021-11113-8. Epub 2022 Jan 9. PMID: 35000081.
67. In 't Veld EH, Keizer R, Post N, Versteeg J, Verdijk R, Naus N, Relyveld G, Crijs M, Smith M, Grünhagen D, Wakkee M, Paridaens D, Zavrakidis I, Mooyaart A, **van Akkooi A**, Strauss D, Verhoef C, Wouters M, Hayes A, van Houdt W. *Outcome after treatment for sebaceous carcinoma: A multicenter study*. *J Surg Oncol*. 2022 Mar;125(4):730-735. doi: 10.1002/jso.26774. Epub 2022 Jan 6. PMID: 34990031; PMCID: PMC9306786.
68. Franken MG, Leeneman B, Aarts MJB, **van Akkooi ACJ**, van den Berkmortel FWPJ, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, van der Veldt AAM, Westgeest HM, Wouters MWJM, Haanen JBAG, Uyl-de Groot CA. *Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs*. *ESMO Open*. 2021 Dec;6(6):100320. doi: 10.1016/j.esmoop.2021.100320. Epub 2021 Nov 29. PMID: 34856511; PMCID: PMC8639434.
69. Levy S, Blankenstein SA, Grünhagen DJ, Jalving M, Hamming-Vrieze O, Been LB, Tans L, **van Akkooi ACJ**, Tesselaar MET. *Postoperative radiotherapy in stage I-III Merkel cell carcinoma*. *Radiother Oncol*. 2022 Jan;166:203-211. doi: 10.1016/j.radonc.2021.11.017. Epub 2021 Nov 25. PMID: 34838887.
70. Stahlie EHA, Carr MJ, Zager JS, **van Akkooi ACJ**. *External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort*. *Ann Surg Oncol*. 2022 Mar;29(3):1637-1644. doi: 10.1245/s10434-021-11111-w. Epub 2021 Nov 23. PMID: 34816368.
71. Eggermont AM, Meshcheryakov A, Atkinson V, Blank CU, Mandala M, Long GV, Barrow C, Di Giacomo AM, Fisher R, Sandhu S, Kudchadkar R, Ortiz Romero PL, Svane IM, Larkin J, Puig S, Hersey P, Quagliano P, Queirolo P, Stroyakovskiy D, Bastholt L, Mohr P, Hernberg M, Chiarion-Sileni

- V, Strother M, Hauschild A, Yamazaki N, **van Akkooi AC**, Lorigan P, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suci S, Robert C. *Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma*. *Eur J Cancer*. 2021 Oct 18;158:156-168. doi: 10.1016/j.ejca.2021.09.023. Epub ahead of print. PMID: 34678677.
72. Carr MJ, Sun J, DePalo D, Rothermel LD, Song Y, Straker RJ, Baecher K, Louie RJ, Stahlie EHA, Wright GP, Naqvi SMH, Kim Y, Sarnaik AA, Karakousis GC, Lowe MC, Delman KA, **van Akkooi ACJ**, Ollila DW, Collichio F, Zager JS. *Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience*. *Ann Surg Oncol*. 2022 Feb;29(2):791-801. doi: 10.1245/s10434-021-10910-5. Epub 2021 Oct 14. PMID: 34648098.
73. de Meza MM, Ismail RK, Rauwerdink D, van Not OJ, van Breeschoten J, Blokk WAM, de Boer A, van Dartel M, Hilarius DL, Ellebaek E, Bonenkamp HJ, Blank CU, Aarts MJB, **van Akkooi ACJ**, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JWB, Haanen JB, Hospers GAP, Kapiteijn EW, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil A, Westgeest HM, van den Eertwegh AJM, Suijkerbuijk KPM, Wouters MWJM. *Adjuvant treatment for melanoma in clinical practice – Trial versus reality*. *Eur J Cancer*. 2021 Nov;158:234-245. doi: 10.1016/j.ejca.2021.08.044. Epub 2021 Sep 29. PMID: 34600790.
74. Reijers SJM, Heerink WJ, Van Veen R, Nijkamp J, Hoetjes NJ, Schrage Y, **Van Akkooi A**, Beets GL, Van Coevorden F, Ruers TJM, Groen HC, Van Houdt WJ. *Surgical navigation for challenging recurrent or pretreated intra-abdominal and pelvic soft tissue sarcomas*. *J Surg Oncol*. 2021 Dec;124(7):1173-1181. doi: 10.1002/jso.26624. Epub 2021 Jul 28. PMID: 34320228.
75. Leeneman B, Schreuder K, Uyl-de Groot CA, **van Akkooi ACJ**, Haanen JBAG, Wakkee M, Franken MG, Louwman MWJ. *Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003-2018): A nationwide population-based study*. *Eur J Cancer*. 2021 Sep;154:111-119. doi: 10.1016/j.ejca.2021.06.007. Epub 2021 Jul 10. PMID: 34256280.
76. Mulder EEAP, Stahlie EHA, Verver D, Lemstra C, Been LB, Mooyaart AL, Brabander T, Vegt E, Verburg FA, van der Veldt AAM, Verhoef C, **van Akkooi ACJ**, Grünhagen DJ. *False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC)*. *J Surg Oncol*. 2021 Dec;124(7):1161-1165. doi: 10.1002/jso.26607. Epub 2021 Jul 8. PMID: 34235758; PMCID: PMC8596632.
77. Jochems A, Bastiaannet E, Aarts MJB, **van Akkooi ACJ**, van den Berkmortel FWPJ, Boers-Sonderen MJ, van den Eertwegh AJM, de Glas NG, de Groot JWB, Haanen JBAG, Hospers GAP, van der Hoeven JJM, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van Zeijl MCT, Kapiteijn E, Wouters MWJM. *Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry*. *J Geriatr Oncol*. 2021 Sep;12(7):1031-1038. doi: 10.1016/j.jgo.2021.04.006. Epub 2021 May 19. PMID: 34020909.
78. Han D, **van Akkooi ACJ**, Straker RJ 3rd, Shannon AB, Karakousis GC, Wang L, Kim KB, Reintgen D. *Current management of melanoma patients with nodal metastases*. *Clin Exp Metastasis*. 2022 Feb;39(1):181-199. doi: 10.1007/s10585-021-10099-7. Epub 2021 May 7. PMID: 33961168; PMCID: PMC8102663.

79. Berger DMS, Verver D, van der Noort V, Grünhagen DJ, Verhoef C, Al-Mamgani A, Zuur CL, **van Akkooi ACJ**, Balm AJM, Klop WMC. *Therapeutic neck dissection in head and neck melanoma patients: Comparing extent of surgery and clinical outcome in two cohorts*. Eur J Surg Oncol. 2021 Sep;47(9):2454-2459. doi: 10.1016/j.ejso.2021.04.007. Epub 2021 Apr 16. PMID: 33867173.
80. Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, **van Akkooi ACJ**, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciú S, Robert C, Eggermont AMM; EORTC Melanoma Group. *Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial*. Lancet Oncol. 2021 May;22(5):655-664. doi: 10.1016/S1470-2045(21)00081-4. Epub 2021 Apr 12. PMID: 33857414.
81. Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, **van Akkooi ACJ**, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciú S, Robert C; EORTC Melanoma Group. *Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial*. Lancet Oncol. 2021 May;22(5):643-654. doi: 10.1016/S1470-2045(21)00065-6. Epub 2021 Apr 12. PMID: 33857412.
82. Blankenstein SA, Rohaan MW, Klop WMC, van der Hiel B, van de Wiel BA, Lahaye MJ, Adriaansz S, Sikorska K, van Tinteren H, Sari A, Grijpink-Ongering LG, van Houdt WJ, Wouters MWJM, Blank CU, Wilgenhof S, van Thienen JV, **van Akkooi ACJ**, Haanen JBAG. *Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial*. Ann Surg. 2021 Aug 1;274(2):383-389. doi: 10.1097/SLA.0000000000004893. PMID: 33843797.
83. Broman KK, Hughes T, Dossett L, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, **van Akkooi A**, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma JM, Deneve JL, Fleming MD, Perez MC, Lowe MC, Olofsson Bagge R, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley G, Hui JYC, Been L, Kruijff S, Kim Y, Naqvi SMH, Sarnaik AA, Sondak VK, Zager JS. *Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2)*. Cancer. 2021 Jul 1;127(13):2251-2261. doi: 10.1002/cncr.33483. Epub 2021 Apr 7. PMID: 33826754; PMCID: PMC8764513.
84. Verver D, Grünhagen DJ, **van Akkooi ACJ**, Aarts MJB, van den Berkmoortel FWPI, van den Eertwegh AJM, de Groot JWB, Boers-Sonderen MJ, Haanen JBAG, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Tije AJT, Vreugdenhil G, Verhoef C, van der Veldt AAM. *Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy*. Cancer Immunol Immunother. 2021 Nov;70(11):3123-3135. doi: 10.1007/s00262-021-02871-1. Epub 2021 Mar 27. PMID: 33774697; PMCID: PMC8505371.

85. Rawson RV, Adhikari C, Bierman C, Lo SN, Shklovskaya E, Rozeman EA, Menzies AM, **van Akkooi ACJ**, Shannon KF, Gonzalez M, Guminski AD, Tetzlaff MT, Stretch JR, Eriksson H, van Thienen JV, Wouters MW, Haanen JBAG, Klop WMC, Zuur CL, van Houdt WJ, Nieweg OE, Ch'ng S, Rizos H, Saw RPM, Spillane AJ, Wilmott JS, Blank CU, Long GV, van de Wiel BA, Scolyer RA. *Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma*. *Ann Oncol*. 2021 Jun;32(6):766-777. doi: 10.1016/j.annonc.2021.03.006. Epub 2021 Mar 17. PMID: 33744385.
86. Versluis JM, Reijers ILM, Rozeman EA, Menzies AM, **van Akkooi ACJ**, Wouters MW, Ch'ng S, Saw RPM, Scolyer RA, van de Wiel BA, Schilling B, Long GV, Blank CU. *Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma*. *Eur J Cancer*. 2021 May;148:51-57. doi: 10.1016/j.ejca.2021.02.012. Epub 2021 Mar 15. PMID: 33735809.
87. Olofsson Bagge R, Ny L, Ascierto PA, Hodi FS, Larkin J, Robert C, Schachter J, Weber JS, Long GV, **van Akkooi ACJ**. *The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials*. *Melanoma Res*. 2021 Apr 1;31(2):181-185. doi: 10.1097/CMR.0000000000000719. PMID: 33625104.
88. Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE, Saw RPM, Xu X, Karakousis GC, Ascierto PA, Spillane AJ, **van Akkooi ACJ**, Davies MA, Mitchell TC, Tawbi HA, Scolyer RA, Wargo JA, Blank CU, Long GV. *Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)*. *Nat Med*. 2021 Feb;27(2):301-309. doi: 10.1038/s41591-020-01188-3. Epub 2021 Feb 8. PMID: 33558722.
89. Rozeman EA, Hoefsmit EP, Reijers ILM, Saw RPM, Versluis JM, Krijgsman O, Dimitriadis P, Sikorska K, van de Wiel BA, Eriksson H, Gonzalez M, Torres Acosta A, Grijpink-Ongering LG, Shannon K, Haanen JBAG, Stretch J, Ch'ng S, Nieweg OE, Mallo HA, Adriaansz S, Kerkhoven RM, Cornelissen S, Broeks A, Klop WMC, Zuur CL, van Houdt WJ, Peeper DS, Spillane AJ, **van Akkooi ACJ**, Scolyer RA, Schumacher TNM, Menzies AM, Long GV, Blank CU. *Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma*. *Nat Med*. 2021 Feb;27(2):256-263. doi: 10.1038/s41591-020-01211-7. Epub 2021 Feb 8. PMID: 33558721.
90. Stahlie EHA, Franke V, Zuur CL, Klop WMC, van der Hiel B, Van de Wiel BA, Wouters MWJM, Schrage YM, van Houdt WJ, **van Akkooi ACJ**. *T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model*. *Cancer Immunol Immunother*. 2021 Aug;70(8):2291-2300. doi: 10.1007/s00262-020-02839-7. Epub 2021 Jan 28. PMID: 33507342.
91. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, **van Akkooi ACJ**, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suci S, Robert C. *Reply to E. Hindié*. *J Clin Oncol*. 2021 Mar 10;39(8):944-946. doi: 10.1200/JCO.20.03463. Epub 2021 Jan 25. PMID: 33492998.
92. Hage JJ, **van Akkooi ACJ**. *The ban of the ipsilateral limb as a skin graft donor site after melanoma excision: A critical review*. *J Plast Reconstr Aesthet Surg*. 2021 Jun;74(6):1303-1308. doi: 10.1016/j.bjps.2020.12.078. Epub 2021 Jan 8. PMID: 33483262.

93. van Zeijl MCT, de Wreede LC, van den Eertwegh AJM, Wouters MWJM, Jochems A, Schouwenburg MG, Aarts MJB, **van Akkooi ACJ**, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van der Hoeven JJM, Haanen JBAG. *Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry*. Eur J Cancer. 2021 Feb;144:242-251. doi: 10.1016/j.ejca.2020.11.028. Epub 2020 Dec 26. PMID: 33373869.
94. **van Akkooi ACJ**, Haferkamp S, Papa S, Franke V, Pinter A, Weishaupt C, Huber MA, Loquai C, Richtig E, Gokani P, Öhrling K, Louie KS, Mohr P. *A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries*. Adv Ther. 2021 Feb;38(2):1245-1262. doi: 10.1007/s12325-020-01590-w. Epub 2020 Dec 26. PMID: 33368016; PMCID: PMC7889564.
95. Stahlie EHA, van der Hiel B, Bruining A, van de Wiel B, Schrage YM, Wouters MWJM, van Houdt WJ, **van Akkooi ACJ**. *The value of lymph node ultrasound and whole body 18F-FDG PET/CT in stage IIB/C melanoma patients prior to SLNB*. Eur J Surg Oncol. 2021 May;47(5):1157-1162. doi: 10.1016/j.ejso.2020.12.007. Epub 2021 Jan 19. PMID: 33353826.
96. Broman KK, Hughes TM, Dossett LA, Sun J, Carr MJ, Kirichenko DA, Sharma A, Bartlett EK, Nijhuis AA, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, **van Akkooi A**, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma J, Deneve JL, Fleming MD, Perez M, Baecher K, Lowe M, Bagge RO, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras RM, Teras J, Farrow NE, Beasley GM, Hui JY, Been L, Kruijff S, Boulware D, Sarnaik AA, Sondak VK, Zager JS; *International High-Risk Melanoma Consortium. Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis*. J Am Coll Surg. 2021 Apr;232(4):424-431. doi: 10.1016/j.jamcollsurg.2020.11.014. Epub 2020 Dec 13. Erratum in: J Am Coll Surg. 2022 Oct 1;235(4):692. PMID: 33316427; PMCID: PMC8764869.
97. Faries MB, Ascierto PA, Blank C, Cochran AJ, Delman K, Gyorki D, Haanen J, Hamid O, Han D, Karakousis G, Kashani-Sabet M, Leachman S, Moncrieff M, Plasmeijer E, Enrico Testori AA, **Van Akkooi A**, Wong S, Zager JS. *Letter Regarding Editorial by Samuel Zagarella*. Am J Dermatopathol. 2021 Jul 1;43(7):539-541. doi: 10.1097/DAD.0000000000001857. PMID: 33264129.
98. Levy S, Aarts MJB, Eskens FALM, Keymeulen KBMI, Been LB, Grünhagen D, **van Akkooi A**, Jalving M, Tesselaar MET. *Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort*. J Immunother Cancer. 2020 Sep;8(2):e001076. doi: 10.1136/jitc-2020-001076. PMID: 32948651; PMCID: PMC7511642.
99. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, **van Akkooi ACJ**, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suci S, Robert C. *Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial*. J Clin Oncol. 2020 Nov 20;38(33):3925-3936. doi: 10.1200/JCO.20.02110. Epub 2020 Sep 18. PMID: 32946353; PMCID: PMC7676886.



100. Stahlie EHA, van der Hiel B, Stokkel MPM, Schrage YM, van Houdt WJ, Wouters MW, **van Akkooi ACJ**. *The use of FDG-PET/CT to detect early recurrence after resection of high-risk stage III melanoma*. J Surg Oncol. 2020 Dec;122(7):1328-1336. doi: 10.1002/jso.26155. Epub 2020 Aug 11. PMID: 32783266.
101. Huis In 't Veld EA, Grünhagen DJ, van Coevorden F, Smith MJ, **van Akkooi AC**, Wouters MWJM, Verhoef C, Strauss DC, Hayes AJ, van Houdt WJ. *Adequate surgical margins for dermatofibrosarcoma protuberans - A multi-centre analysis*. Eur J Surg Oncol. 2021 Feb;47(2):436-442. doi: 10.1016/j.ejso.2020.06.022. Epub 2020 Jul 7. PMID: 32773140.
102. Boshuizen J, Vredevoogd DW, Krijgsman O, Ligtenberg MA, Blankenstein S, de Bruijn B, Frederick DT, Kenski JCN, Parren M, Brüggemann M, Madu MF, Rozeman EA, Song JY, Horlings HM, Blank CU, **van Akkooi ACJ**, Flaherty KT, Boland GM, Peeper DS. *Reversal of pre-existing NGFR-driven tumor and immune therapy resistance*. Nat Commun. 2020 Aug 7;11(1):3946. doi: 10.1038/s41467-020-17739-8. Erratum in: Nat Commun. 2023 Feb 7;14(1):672. PMID: 32770055; PMCID: PMC7414147.
103. Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, **van Akkooi A**, Arance A, Blank CU, Chiarion Sileni V, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, Olofsson Bagge R, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Michielin O. *ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee*. Ann Oncol. 2020 Nov;31(11):1435-1448. doi: 10.1016/j.annonc.2020.07.004. Epub 2020 Aug 4. PMID: 32763453.
104. Michielin O, **van Akkooi A**, Lorigan P, Ascierto PA, Dummer R, Robert C, Arance A, Blank CU, Chiarion Sileni V, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, Olofsson Bagge R, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Keilholz U. *ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee*. Ann Oncol. 2020 Nov;31(11):1449-1461. doi: 10.1016/j.annonc.2020.07.005. Epub 2020 Aug 4. PMID: 32763452.
105. Testori AAE, Chiellino S, **van Akkooi ACJ**. *Adjuvant Therapy for Melanoma: Past, Current, and Future Developments*. Cancers (Basel). 2020 Jul 21;12(7):1994. doi: 10.3390/cancers12071994. PMID: 32708268; PMCID: PMC7409361.
106. Olofsson Bagge R, Kicinski M, Faries MB, Gyorki DE, Isaksson K, Katsarelis D, Lo S, Moncrieff M, Spillane A, Suci S, **van Akkooi A**. *Comment on "Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram"*. J Clin Oncol. 2020 Sep 20;38(27):3233-3234. doi: 10.1200/JCO.20.01680. Epub 2020 Jul 23. PMID: 32701414.
107. Franke V, Madu MF, Bierman C, Klop WMC, van Houdt WJ, Wouters MWJM, van de Wiel BA, **van Akkooi ACJ**. *Challenges in sentinel node pathology in the era of adjuvant treatment*. J Surg Oncol. 2020 Oct;122(5):964-972. doi: 10.1002/jso.26095. Epub 2020 Jun 29. PMID: 32602119.
108. van Veenendaal LM, Bertolli E, Korse CM, Klop WMC, Tesselaar MET, **van Akkooi ACJ**. *The Clinical Utility of Neuron-Specific Enolase (NSE) Serum Levels as a Biomarker for Merkel Cell*



*Carcinoma (MCC)*. Ann Surg Oncol. 2021 Feb;28(2):1019-1028. doi: 10.1245/s10434-020-08656-7. Epub 2020 Jun 11. PMID: 32529274.

109. Franke V, Smeets PMG, van der Wal JE, **van Akkooi ACJ**. *Complete response to talimogene laherparepvec in a primary acral lentiginous melanoma*. Melanoma Res. 2020 Dec;30(6):548-551. doi: 10.1097/CMR.0000000000000673. PMID: 32516238.
110. van Veenendaal LM, **van Akkooi ACJ**. *ASO Author Reflections: Neuron-Specific Enolase as a Valuable Biomarker for Patients with Merkel Cell Carcinoma in the Era of Immunotherapy*. Ann Surg Oncol. 2020 Dec;27(Suppl 3):769-770. doi: 10.1245/s10434-020-08675-4. Epub 2020 May 30. PMID: 32474817.
111. Eggermont AMM, Rutkowski P, Dutriaux C, Hofman-Wellenhof R, Dzierwulski P, Marples M, Grange F, Lok C, Pennachioli E, Robert C, **van Akkooi ACJ**, Bastholt L, Minisini A, Marshall E, Salès F, Grob JJ, Bechter O, Schadendorf D, Marreaud S, Kicinski M, Suciu S, Testori AAE. *Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial*. Eur J Cancer. 2020 Jul;133:94-103. doi: 10.1016/j.ejca.2020.04.015. Epub 2020 May 26. PMID: 32470710.
112. Verver D, Rekkas A, Garbe C, van Klaveren D, **van Akkooi ACJ**, Rutkowski P, Powell BWEM, Robert C, Testori A, van Leeuwen BL, van der Veldt AAM, Keilholz U, Stadler R, Eggermont AMM, Verhoef C, Leiter U, Grünhagen DJ. *The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection*. Eur J Cancer. 2020 Jul;134:9-18. doi: 10.1016/j.ejca.2020.04.022. Epub 2020 May 23. PMID: 32454396.
113. Spillane AJ, Menzies AM, **van Akkooi ACJ**. *The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients - A Potential Paradigm Shift in Management*. Ann Surg Oncol. 2020 Jul;27(7):2188-2200. doi: 10.1245/s10434-020-08566-8. Epub 2020 May 14. PMID: 32409966.
114. Blankenstein SA, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, van den Eertwegh AJM, Franken MG, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, **van Akkooi ACJ**. *Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy*. Cancers (Basel). 2020 May 7;12(5):1176. doi: 10.3390/cancers12051176. PMID: 32392717; PMCID: PMC7281176.
115. **van Akkooi ACJ**, Spillane AJ. *ASO Author Reflections: The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients: A Potential Paradigm Shift in Management*. Ann Surg Oncol. 2020 Jul;27(7):2201-2202. doi: 10.1245/s10434-020-08570-y. Epub 2020 May 7. PMID: 32382889.
116. Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, **van Akkooi ACJ**, van den Braber M, Rozeman EA, Haanen JBAG, Blank CU, Horlings HM, David E, Baran Y, Bercovich A, Lifshitz A, Schumacher TN, Tanay A, Amit I. *Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma*. Cell. 2020 Apr 30;181(3):747. doi: 10.1016/j.cell.2020.04.017. Erratum for: Cell. 2019 Feb 7;176(4):775-789.e18. PMID: 32359441.

117. Hartemink KJ, **van Akkooi ACJ**, Houwink API, Voest EE. *Patients with cancer in the era of 2019 novel coronavirus disease*. Eur J Cancer. 2020 Jun;132:125-126. doi: 10.1016/j.ejca.2020.03.019. Epub 2020 Apr 27. PMID: 32353785; PMCID: PMC7184997.
118. Leeneman B, Uyl-de Groot CA, Aarts MJB, **van Akkooi ACJ**, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, Herbschleb KH, van der Hoeven JJM, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Haanen JBAG, Franken MG. *Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs*. Cancers (Basel). 2020 Apr 18;12(4):1003. doi: 10.3390/cancers12041003. PMID: 32325748; PMCID: PMC7225943.
119. Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA, Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, **van Akkooi A**, Funchain P. *Systemic Therapy for Melanoma: ASCO Guideline*. J Clin Oncol. 2020 Nov 20;38(33):3947-3970. doi: 10.1200/JCO.20.00198. Epub 2020 Mar 31. Erratum in: J Clin Oncol. 2023 Dec 1;41(34):5331. PMID: 32228358.
120. Blankenstein SA, **van Akkooi ACJ**. *Broadening indications for neoadjuvant immunotherapy*. Br J Dermatol. 2020 Sep;183(3):421-422. doi: 10.1111/bjd.18873. Epub 2020 Feb 3. PMID: 32017031.
121. Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, **van Akkooi A**, Robert C, Suci S. *Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial*. JAMA Oncol. 2020 Apr 1;6(4):519-527. doi: 10.1001/jamaoncol.2019.5570. PMID: 31895407; PMCID: PMC6990933.
122. Testori AAE, Blankenstein SA, **van Akkooi ACJ**. *Primary Melanoma: from History to Actual Debates*. Curr Oncol Rep. 2019 Dec 19;21(12):112. doi: 10.1007/s11912-019-0843-x. PMID: 31858280.
123. Stahlie EHA, Blankenstein SA, van Houdt WJ, Wouters MWJM, **van Akkooi ACJ**. *Comment on "Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does Not Provide Reliable Nodal Staging: Results From a Large Multicenter Trial"*. Ann Surg. 2021 Jul 1;274(1):e103-e104. doi: 10.1097/SLA.0000000000003696. PMID: 31850978.
124. Schouwenburg MG, Suijkerbuijk KPM, Koornstra RHT, Jochems A, van Zeijl MCT, van den Eertwegh AJM, Haanen JBAG, Aarts MJ, **Akkooi ACJV**, Berkmortel FWPJVD, Groot JWB, Hospers GAP, Kapiteijn E, Kruit WH, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Hoeven JJMV, Wouters MWJM. *Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy: The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?* Cancers (Basel). 2019 Dec 4;11(12):1940. doi: 10.3390/cancers11121940. PMID: 31817189; PMCID: PMC6966631.

125. Testori AAE, Blankenstein SA, **van Akkooi ACJ**. *Surgery for Metastatic Melanoma: an Evolving Concept*. *Curr Oncol Rep*. 2019 Nov 6;21(11):98. doi: 10.1007/s11912-019-0847-6. PMID: 31696407.
126. Madu MF, Franke V, Van de Wiel BA, Klop WMC, Jóźwiak K, van Houdt WJ, Wouters MWJM, **van Akkooi ACJ**. *External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?* *Melanoma Res*. 2020 Apr;30(2):185-192. doi: 10.1097/CMR.0000000000000643. PMID: 31651715.
127. Michielin O, **van Akkooi ACJ**, Ascierto PA, Dummer R, Keilholz U; *ESMO Guidelines Committee*. *Electronic address: clinicalguidelines@esmo.org*. *Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†*. *Ann Oncol*. 2019 Dec 1;30(12):1884-1901. doi: 10.1093/annonc/mdz411. PMID: 31566661.
128. Stahlie EHA, Blankenstein SA, van Houdt WJ, Wouters MWJM, **van Akkooi ACJ**. *A systematic review and meta-analysis of locoregional treatments for in-transit melanoma*. *J Surg Oncol*. 2019 Nov;120(6):1056-1057. doi: 10.1002/jso.25685. Epub 2019 Aug 22. PMID: 31441058.
129. Verver D, van der Veldt AAM, **van Akkooi ACJ**, Verhoef K, Grünhagen DJ, Louwman MWJ. *Author's reply to: The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous*. *Int J Cancer*. 2019 Dec 1;145(11):3175-3176. doi: 10.1002/ijc.32630. Epub 2019 Sep 3. PMID: 31423580.
130. Schuurman MS, Hollestein LM, Bastiaannet E, Posthuma EFM, **van Akkooi AJC**, Kukutsch NA, Aarts MJB, Wakkee M, Lemmens VEPP, Louwman MWJ. *Melanoma in older patients: declining gap in survival between younger and older patients with melanoma*. *Acta Oncol*. 2020 Jan;59(1):4-12. doi: 10.1080/0284186X.2019.1643914. Epub 2019 Jul 26. PMID: 31347929.
131. Jochems A, van der Kooij MK, Fiocco M, Schouwenburg MG, Aarts MJ, **van Akkooi AC**, van den Berkmortel FWPJ, Blank CU, van den Eertwegh AJM, Franken MG, de Groot JB, Haanen JBAG, Hospers GAP, Koornstra RH, Kruit WHJ, Louwman M, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van Zeijl MCT, van der Hoeven KJM, Kapiteijn E. *Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry*. *Cancers (Basel)*. 2019 Jul 18;11(7):1007. doi: 10.3390/cancers11071007. PMID: 31323802; PMCID: PMC6678641.
132. Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members; Ascierto PA, Spillane AJ, **van Akkooi ACJ**, Wargo JA, Blank CU, Tawbi HA, Long GV. *Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium*. *Lancet Oncol*. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. PMID: 31267972.
133. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, **van Akkooi AC**, Suci S, Robert C. *Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-*

*054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.* Eur J Cancer. 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020. Epub 2019 Jun 11. PMID: 31200321.

134. Rozeman EA, Menzies AM, **van Akkooi ACJ**, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Acosta AT, Ter Meulen S, Koenen AM, Bosch LJW, Shannon K, Pronk LM, Gonzalez M, Ch'ng S, Griepink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peeper DS, Spillane AJ, Hansson J, Schumacher TN, Long GV, Blank CU. *Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.* Lancet Oncol. 2019 Jul;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2. Epub 2019 May 31. PMID: 31160251.
135. Ascierto PA, Bruzzi P, Eggermont A, Hamid O, Tawbi HA, **van Akkooi A**, Testori A, Caracò C, Puzanov I, Perrone F. *The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.* J Transl Med. 2019 May 10;17(1):148. doi: 10.1186/s12967-019-1892-5. PMID: 31077205; PMCID: PMC6509811.
136. Cook MG, Massi D, Szumera-Ciećkiewicz A, Van den Oord J, Blokx W, van Kempen LC, Balamurugan T, Bosisio F, Koljenović S, Portelli F, **van Akkooi ACJ**; EORTC Melanoma Group. *An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma.* Eur J Cancer. 2019 Jun;114:1-7. doi: 10.1016/j.ejca.2019.03.010. Epub 2019 Apr 17. PMID: 31005015.
137. Blankenstein SA, **van Akkooi ACJ**. *Adjuvant systemic therapy in high-risk melanoma.* Melanoma Res. 2019 Aug;29(4):358-364. doi: 10.1097/CMR.0000000000000604. PMID: 30896556.
138. Schermers B, Franke V, Rozeman EA, van de Wiel BA, Bruining A, Wouters MW, van Houdt WJ, Ten Haken B, Muller SH, Bierman C, Ruers TJM, Blank CU, **van Akkooi ACJ**. *Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma.* Br J Surg. 2019 Apr;106(5):519-522. doi: 10.1002/bjs.11168. Epub 2019 Mar 18. PMID: 30882901; PMCID: PMC6593699.
139. Franke V, **van Akkooi ACJ**. *The extent of surgery for stage III melanoma: how much is appropriate?* Lancet Oncol. 2019 Mar;20(3):e167-e174. doi: 10.1016/S1470-2045(19)30099-3. PMID: 30842060.
140. van Veenendaal LM, Madu MF, Tesselaar MET, Verhoef CK, Grünhagen DJ, **van Akkooi ACJ**. *Reply to: Letter re: Efficacy of isolated limb perfusion (ILP) in patients with Merkel cell carcinoma: A multicenter experience.* Eur J Surg Oncol. 2019 Jun;45(6):1122-1123. doi: 10.1016/j.ejso.2019.02.020. Epub 2019 Feb 16. PMID: 30808525.
141. Verver D, van der Veldt A, **van Akkooi A**, Verhoef C, Grünhagen DJ, Louwman WJ. *Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population-based study.* Int J Cancer. 2020 Jan 1;146(1):26-34. doi: 10.1002/ijc.32229. Epub 2019 Mar 20. PMID: 30801710; PMCID: PMC6900034.
142. Berger DMS, van Veen MM, Madu MF, **van Akkooi ACJ**, Vogel WV, Balm AJM, Klop WMC. *Parotidectomy in patients with head and neck cutaneous melanoma with cervical lymph node*

- involvement*. Head Neck. 2019 Jul;41(7):2264-2270. doi: 10.1002/hed.25670. Epub 2019 Feb 14. PMID: 30762921.
143. Uitentuis SE, Louwman MWJ, **van Akkooi ACJ**, Bekkenk MW. *Treatment and survival of Merkel cell carcinoma since 1993: A population-based cohort study in The Netherlands*. J Am Acad Dermatol. 2019 Oct;81(4):977-983. doi: 10.1016/j.jaad.2019.01.042. Epub 2019 Jan 29. PMID: 30703452.
144. Franke V, Berger DMS, Klop WMC, van der Hiel B, van de Wiel BA, Ter Meulen S, Wouters MWJM, van Houdt WJ, **van Akkooi ACJ**. *High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a)*. Int J Cancer. 2019 Aug 15;145(4):974-978. doi: 10.1002/ijc.32172. Epub 2019 Feb 21. PMID: 30694555.
145. Huis In 't Veld EA, van Coevorden F, Grünhagen DJ, Smith MJ, **van Akkooi ACJ**, Wouters MWJM, Hayes AJ, Verhoef C, Strauss DC, van Houdt WJ. *Outcome after surgical treatment of dermatofibrosarcoma protuberans: Is clinical follow-up always indicated?* Cancer. 2019 Mar 1;125(5):735-741. doi: 10.1002/cncr.31924. Epub 2019 Jan 15. PMID: 30644528.
146. **van Akkooi ACJ**, Hayes A. *Recent developments in lymph node surgery for melanoma*. Br J Dermatol. 2019 Jan;180(1):5-7. doi: 10.1111/bjd.17143. PMID: 30604533.
147. Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, **van Akkooi ACJ**, van den Braber M, Rozeman EA, Haanen JBAG, Blank CU, Horlings HM, David E, Baran Y, Bercovich A, Lifshitz A, Schumacher TN, Tanay A, Amit I. *Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma*. Cell. 2019 Feb 7;176(4):775-789.e18. doi: 10.1016/j.cell.2018.11.043. Epub 2018 Dec 27. Erratum in: Cell. 2020 Apr 30;181(3):747. PMID: 30595452; PMCID: PMC7253294.
148. Bertolli E, Franke V, Calsavara VF, de Macedo MP, Pinto CAL, van Houdt WJ, Wouters MWJM, Duprat Neto JP, **van Akkooi ACJ**. *Validation of a Nomogram for Non-sentinel Node Positivity in Melanoma Patients, and Its Clinical Implications: A Brazilian-Dutch Study*. Ann Surg Oncol. 2019 Feb;26(2):395-405. doi: 10.1245/s10434-018-7038-9. Epub 2018 Nov 19. PMID: 30456681.
149. Lansu J, Groenewegen J, van Coevorden F, van Houdt W, **van Akkooi ACJ**, van Boven H, van de Sande M, Verheij M, Haas RL. *Time dependent dynamics of wound complications after preoperative radiotherapy in Extremity Soft Tissue Sarcomas*. Eur J Surg Oncol. 2019 Apr;45(4):684-690. doi: 10.1016/j.ejso.2018.09.001. Epub 2018 Oct 6. PMID: 30316565.
150. Verver D, van Klaveren D, Franke V, **van Akkooi ACJ**, Rutkowski P, Keilholz U, Eggermont AMM, Nijsten T, Grünhagen DJ, Verhoef C. *Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes*. Br J Surg. 2019 Feb;106(3):217-225. doi: 10.1002/bjs.10995. Epub 2018 Oct 11. PMID: 30307046; PMCID: PMC6585628.
151. Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, Krijgsman O, van den Braber M, Philips D, Broeks A, van Thienen JV, Mallo HA, Adriaansz S, Ter Meulen S, Pronk LM, Grijpink-Ongering LG, Bruining A, Gittelman RM, Warren S, van Tinteren H, Peeper DS, Haanen JBAG, **van Akkooi ACJ**, Schumacher TN. *Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma*. Nat Med. 2018 Nov;24(11):1655-1661. doi: 10.1038/s41591-018-0198-0. Epub 2018 Oct 8. PMID: 30297911.



152. Schadendorf D, **van Akkooi ACJ**, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S. *Melanoma*. Lancet. 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9. Erratum in: Lancet. 2019 Feb 23;393(10173):746. PMID: 30238891.
153. Kudchadkar RR, Michielin O, **van Akkooi ACJ**. *Practice-Changing Developments in Stage III Melanoma: Surgery, Adjuvant Targeted Therapy, and Immunotherapy*. Am Soc Clin Oncol Educ Book. 2018 May 23;38:759-762. doi: 10.1200/EDBK\_200241. PMID: 30231370.
154. Sommariva A, Forsea AM, Agius D, Ascierto PA, Bastiaannet E, Borgognoni L, Demetriou A, Garbe C, Gavric Z, Hocevar M, Innos K, Larønningen S, Louwman M, Robsahm TE, Rutkowski P, **van Akkooi A**, Zorzi M, Pasquali S, van de Velde C, Rossi CR. *Quality assurance in melanoma care: The EU-MELACARE study*. Eur J Surg Oncol. 2018 Nov;44(11):1773-1778. doi: 10.1016/j.ejso.2018.06.020. Epub 2018 Jul 3. PMID: 30001892.
155. Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, **van Akkooi ACJ**, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA. *Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma*. Ann Oncol. 2018 Aug 1;29(8):1861-1868. doi: 10.1093/annonc/mdy226. PMID: 29945191; PMCID: PMC6096739.
156. van Veenendaal LM, **van Akkooi ACJ**, Verhoef C, Grünhagen DJ, Klop WMC, Valk GD, Tesselaar MET. *Merkel cell carcinoma: Clinical outcome and prognostic factors in 351 patients*. J Surg Oncol. 2018 Jun;117(8):1768-1775. doi: 10.1002/jso.25090. Epub 2018 May 22. PMID: 29790179.
157. Schouwenburg MG, Jochems A, Leeneman B, Franken MG, van den Eertwegh AJM, Haanen JBAG, van Zeijl MCT, Aarts MJ, **van Akkooi ACJ**, van den Berkmoortel FWPI, Blokk WAM, de Groot JWB, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van der Hoeven JJM. *Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes*. Melanoma Res. 2018 Aug;28(4):326-332. doi: 10.1097/CMR.0000000000000453. PMID: 29750749.
158. Verver D, Oude Ophuis CMC, Koppert LB, de Monyé C, van Deurzen CHM, Koljenović S, Bruining A, van der Hiel B, Ter Meulen S, **van Akkooi ACJ**, Verhoef C, Grünhagen DJ. *Gamma probe and ultrasound-guided fine needle aspiration cytology of the sentinel node (GULF) trial*. Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1926-1933. doi: 10.1007/s00259-018-4014-3. Epub 2018 Apr 26. PMID: 29700573; PMCID: PMC6132503.
159. Verver D, van Klaveren D, **van Akkooi ACJ**, Rutkowski P, Powell BWEM, Robert C, Testori A, van Leeuwen BL, van der Veldt AAM, Keilholz U, Eggermont AMM, Verhoef C, Grünhagen DJ. *Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations*. Eur J Cancer. 2018 Jun;96:25-33. doi: 10.1016/j.ejca.2018.02.022. Epub 2018 Apr 13. PMID: 29660597.
160. Jochems A, Leeneman B, Franken MG, Schouwenburg MG, Aarts MJB, **van Akkooi ACJ**, van den Berkmoortel FWPI, van den Eertwegh AJM, Groenewegen G, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Ten



- Tije AJ, Vreugdenhil G, Wouters MWJM, Uyl-de Groot CA, van der Hoeven KJM. *Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands*. *Anticancer Drugs*. 2018 Jul;29(6):572-578. doi: 10.1097/CAD.0000000000000629. PMID: 29659371.
161. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, **van Akkooi ACJ**, Suci S, Robert C. *Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma*. *N Engl J Med*. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15. PMID: 29658430.
162. Franken MG, Leeneman B, Jochems A, Schouwenburg MG, Aarts MJB, **van Akkooi ACJ**, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, van der Hoeven KJM, Hospers GAP, Kapiteijn E, Koornstra R, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van Zeijl M, Haanen JBAG, Uyl-de Groot CA. *Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands*. *Anticancer Drugs*. 2018 Jul;29(6):579-588. doi: 10.1097/CAD.0000000000000628. PMID: 29634490.
163. Testori AA, Suci S, **van Akkooi ACJ**, Suppa M, Eggermont AMM, de Vries E, Joosse A; *European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group*. *Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies*. *Melanoma Res*. 2018 Jun;28(3):222-229. doi: 10.1097/CMR.0000000000000433. PMID: 29432281.
164. Grob JJ, Schadendorf D, Lorigan P, Ascierto P, Larkin J, Nathan P, Robert C, Hauschild A, Weber J, Daud A, Hamid O, Dummer R, Hansson J, Hoeller C, Schachter J, **Van Akkooi ACJ**, Garbe C. *Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III*. *Eur J Cancer*. 2018 Mar;91:168-170. doi: 10.1016/j.ejca.2017.11.023. Epub 2017 Dec 7. PMID: 29224903.
165. Franke V, van der Hiel B, van de Wiel BA, Klop WMC, Ter Meulen S, **van Akkooi ACJ**. *Positron emission tomography/computed tomography evaluation of oncolytic virus therapy efficacy in melanoma*. *Eur J Cancer*. 2018 Feb;90:149-152. doi: 10.1016/j.ejca.2017.11.007. Epub 2017 Dec 8. PMID: 29224902.
166. Verver D, Louwman WJ, Koljenović S, Verhoef C, Grünhagen DJ, **van Akkooi ACJ**. *Improved stratification of pT1 melanoma according to the 8th American Joint Committee on Cancer staging edition criteria: A Dutch population-based study*. *Eur J Cancer*. 2018 Mar;92:100-107. doi: 10.1016/j.ejca.2017.10.031. Epub 2017 Dec 5. PMID: 29217356.
167. Voit CA, **van Akkooi ACJ**, Catalano O, Eggermont AMM. *Pre-SN Ultrasound-FNAC can be Sensitive for Lymph Node Metastases in Melanoma Patients if Performed with the Use of the Berlin Criteria*. *Ann Surg Oncol*. 2017 Dec;24(Suppl 3):661-662. doi: 10.1245/s10434-017-6230-7. Epub 2017 Nov 20. PMID: 29159735.
168. Madu MF, van de Wiel B, **van Akkooi ACJ**. *Comment: Detailed Pathologic Examination of Completion Node Dissection Specimens and Outcome for Melanoma Patients with Minimal*

- (< 0.1 mm) Sentinel Lymph Node Metastases. *Ann Surg Oncol*. 2017 Dec;24(Suppl 3):658-659. doi: 10.1245/s10434-017-6169-8. Epub 2017 Nov 7. PMID: 29116486.
169. Verver D, Madu MF, Oude Ophuis CMC, Faut M, de Wilt JHW, Bonenkamp JJ, Grünhagen DJ, **van Akkooi ACJ**, Verhoef C, van Leeuwen BL. *Optimal extent of completion lymphadenectomy for patients with melanoma and a positive sentinel node in the groin*. *Br J Surg*. 2018 Jan;105(1):96-105. doi: 10.1002/bjs.10644. Epub 2017 Nov 2. PMID: 29095479; PMCID: PMC5765473.
170. Madu MF, Franke V, Bruin MM, Berger DMS, Bierman C, Józwiak K, Klop WMC, Wouters MWJM, **van Akkooi ACJ**, Van de Wiel BA. *Immediate completion lymph node dissection in stage IIIA melanoma does not provide significant additional staging information beyond EORTC SN tumour burden criteria*. *Eur J Cancer*. 2017 Dec;87:212-215. doi: 10.1016/j.ejca.2017.09.002. Epub 2017 Oct 3. PMID: 28986137.
171. Huis In 't Veld EA, Grünhagen DJ, Verhoef C, Smith HG, **van Akkooi ACJ**, Jones R, van Coevorden F, Hayes AJ, van Houdt WJ. *Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study*. *Eur J Cancer*. 2017 Nov;85:114-121. doi: 10.1016/j.ejca.2017.07.023. Epub 2017 Sep 15. PMID: 28918185.
172. van Veenendaal LM, Madu MF, Tesselaar MET, Verhoef C, Grünhagen DJ, **van Akkooi ACJ**. *Efficacy of isolated limb perfusion (ILP) in patients with Merkel cell carcinoma (MCC): A multicenter experience*. *Eur J Surg Oncol*. 2017 Nov;43(11):2157-2162. doi: 10.1016/j.ejso.2017.07.015. Epub 2017 Aug 3. PMID: 28802661.
173. Farag S, van der Kolk LE, van Boven HH, **van Akkooi ACJ**, Beets GL, Wilmink JW, Steeghs N. *Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview*. *Fam Cancer*. 2018 Apr;17(2):247-253. doi: 10.1007/s10689-017-0024-8. PMID: 28710566.
174. Oude Ophuis CMC, Koppert LB, de Monyé C, van Deurzen CHM, Koljenović S, **van Akkooi ACJ**, Verhoef C, Grünhagen DJ. *Erratum to: gamma probe and ultrasound guided fine needle aspiration cytology of the sentinel node (GULF) trial - overview of the literature, pilot and study protocol*. *BMC Cancer*. 2017 May 30;17(1):387. doi: 10.1186/s12885-017-3363-9. Erratum for: *BMC Cancer*. 2017 Apr 12;17(1):258. PMID: 28558666; PMCID: PMC5450197.
175. Madu MF, Schopman JHH, Berger DMS, Klop WMC, Józwiak K, Wouters MWJM, van der Hage JA, **van Akkooi ACJ**. *Clinical prognostic markers in stage IIIC melanoma*. *J Surg Oncol*. 2017 Aug;116(2):244-251. doi: 10.1002/jso.24635. Epub 2017 Apr 15. PMID: 28411392.
176. Oude Ophuis CMC, Koppert LB, de Monyé C, van Deurzen CHM, Koljenović S, **van Akkooi ACJ**, Verhoef C, Grünhagen DJ. *Gamma probe and ultrasound guided fine needle aspiration cytology of the sentinel node (GULF) trial - overview of the literature, pilot and study protocol*. *BMC Cancer*. 2017 Apr 12;17(1):258. doi: 10.1186/s12885-017-3236-2. Erratum in: *BMC Cancer*. 2017 May 30;17(1):387. PMID: 28403815; PMCID: PMC5389093.
177. Oude Ophuis CMC, Verhoef C, Grünhagen DJ, Siegel P, Schoengen A, Röwert-Huber J, Eggermont AMM, Voit CA, **van Akkooi ACJ**. *Long-term results of ultrasound guided fine needle aspiration cytology in conjunction with sentinel node biopsy support step-wise approach in*

- melanoma*. Eur J Surg Oncol. 2017 Aug;43(8):1509-1516. doi: 10.1016/j.ejso.2017.02.009. Epub 2017 Feb 21. PMID: 28262276.
178. Madu MF, Timmerman P, Wouters MWJM, van der Hiel B, van der Hage JA, **van Akkooi ACJ**. *PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study*. Melanoma Res. 2017 Jun;27(3):251-257. doi: 10.1097/CMR.0000000000000347. PMID: 28225434.
179. Oude Ophuis CM, **van Akkooi AC**, Rutkowski P, Powell WE, Robert C, Testori A, van Leeuwen BL, Siegel P, Eggermont AM, Verhoef C, Grünhagen DJ. *Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma*. Br J Surg. 2017 May;104(6):726-733. doi: 10.1002/bjs.10475. Epub 2017 Feb 20. PMID: 28218385.
180. Madu MF, Deken MM, van der Hage JA, Józwiak K, Wouters MWJM, **van Akkooi ACJ**. *Isolated Limb Perfusion for Melanoma is Safe and Effective in Elderly Patients*. Ann Surg Oncol. 2017 Jul;24(7):1997-2005. doi: 10.1245/s10434-017-5803-9. Epub 2017 Feb 10. PMID: 28188500.
181. Oude Ophuis CM, Louwman MW, Grünhagen DJ, Verhoef K, **van Akkooi AC**. *Implementation of the 7th edition AJCC staging system: Effects on staging and survival for pT1 melanoma. A Dutch population based study*. Int J Cancer. 2017 Apr 15;140(8):1802-1808. doi: 10.1002/ijc.30607. Epub 2017 Feb 7. PMID: 28109000.
182. Ribero S, Pampena R, Bataille V, Moscarella E, Thomas L, Quaglino P, Potenza C, **Van Akkooi ACJ**, Testori A, Nathan P, Puig S, Zalaudek I, Argenziano G, Longo C. *Unknown Primary Melanoma: Worldwide Survey on Clinical Management*. Dermatology. 2016;232(6):704-707. doi: 10.1159/000453592. Epub 2017 Jan 5. PMID: 28052277.
183. Madu M, Wouters MW, **van Akkooi AC**. *Reply to "Current controversies on sentinel node biopsy in thin and thick cutaneous melanoma"*. Eur J Surg Oncol. 2017 Feb;43(2):508. doi: 10.1016/j.ejso.2016.10.018. Epub 2016 Nov 5. PMID: 27847285.
184. Madu MF, Wouters MW, Klop WM, van der Hiel B, van de Wiel BA, Józwiak K, van der Hage JA, **van Akkooi AC**. *Clinical Prognostic Markers in Stage IIIB Melanoma*. Ann Surg Oncol. 2016 Dec;23(13):4195-4202. doi: 10.1245/s10434-016-5396-8. Epub 2016 Jul 5. PMID: 27380642.
185. Oude Ophuis CM, **van Akkooi AC**, Rutkowski P, Voit CA, Stepniak J, Erler NS, Eggermont AM, Wouters MW, Grünhagen DJ, Verhoef CK. *Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival*. Eur J Cancer. 2016 Nov;67:164-173. doi: 10.1016/j.ejca.2016.08.014. Epub 2016 Sep 24. PMID: 27669503.
186. Madu MF, Wouters MW, **van Akkooi AC**. *Sentinel node biopsy in melanoma: Current controversies addressed*. Eur J Surg Oncol. 2017 Mar;43(3):517-533. doi: 10.1016/j.ejso.2016.08.007. Epub 2016 Aug 24. PMID: 27590685.
187. Oude Ophuis CM, Verhoef C, Rutkowski P, Powell BW, van der Hage JA, van Leeuwen PA, Voit CA, Testori A, Robert C, Hoekstra HJ, Grünhagen DJ, Eggermont AM, **van Akkooi AC**. *The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group study*. Eur J Surg Oncol. 2016 Dec;42(12):1906-1913. doi: 10.1016/j.ejso.2016.05.012. Epub 2016 May 27. PMID: 27266406.

188. **van Akkooi AC**, Atkins MB, Agarwala SS, Lorigan P. *Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma*. Am Soc Clin Oncol Educ Book. 2016;35:e505-14. doi: 10.1200/EDBK\_159087. PMID: 27249760.
189. van der Ploeg IM, Madu MF, van der Hage JA, Wouters MW, Klop WM, van der Hiel B, van de Wiel BA, **van Akkooi AJ**. *Blue dye can be safely omitted in most sentinel node procedures for melanoma*. Melanoma Res. 2016 Oct;26(5):464-8. doi: 10.1097/CMR.000000000000271. PMID: 27232099.
190. van den Berg NS, Miwa M, KleinJan GH, Sato T, Maeda Y, **van Akkooi AC**, Horenblas S, Karakullukcu B, van Leeuwen FW. *(Near-Infrared) Fluorescence-Guided Surgery Under Ambient Light Conditions: A Next Step to Embedment of the Technology in Clinical Routine*. Ann Surg Oncol. 2016 Aug;23(8):2586-95. doi: 10.1245/s10434-016-5186-3. Epub 2016 Mar 28. PMID: 27020586; PMCID: PMC4927603.
191. Madu M, **van Akkooi AC**. *Response to Wheatley et al., "Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation"*, Cancer Treatment Reviews. Cancer Treat Rev. 2016 Apr;45:76. doi: 10.1016/j.ctrv.2016.03.008. Epub 2016 Mar 14. PMID: 26994326.
192. van Wissen J, van der Hiel B, van der Hage JA, van de Wiel BA, Wouters MW, **van Akkooi AC**. *The Diagnostic Value of PET/CT Imaging in Melanoma Groin Metastases*. Ann Surg Oncol. 2016 Jul;23(7):2323-9. doi: 10.1245/s10434-016-5142-2. Epub 2016 Feb 26. PMID: 26920386.
193. Voit CA, Oude Ophuis CM, Ulrich J, **van Akkooi AC**, Eggermont AM. *Ultrasound of the sentinel node in melanoma patients: echo-free island is a discriminatory morphologic feature for node positivity*. Melanoma Res. 2016 Jun;26(3):267-71. doi: 10.1097/CMR.000000000000223. PMID: 26881876.
194. Voit CA, **van Akkooi AC**. *Making Peace With Cancer*. J Clin Oncol. 2015 Dec 10;33(35):4227-8. doi: 10.1200/JCO.2015.63.1333. Epub 2015 Oct 12. PMID: 26460307.
195. Oude Ophuis CM, **van Akkooi AC**, Hoekstra HJ, Bonenkamp JJ, van Wissen J, Niebling MG, de Wilt JH, van der Hiel B, van de Wiel B, Koljenović S, Grünhagen DJ, Verhoef C. *Risk Factors for Positive Deep Pelvic Nodal Involvement in Patients with Palpable Groin Melanoma Metastases: Can the Extent of Surgery be Safely Minimized? : A Retrospective, Multicenter Cohort Study*. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1172-80. doi: 10.1245/s10434-015-4602-4. Epub 2015 May 27. PMID: 26014150; PMCID: PMC4686555.
196. **van Akkooi AC**, Kukutsch NA, Soetekouw P. *Schildwachtklierprocedure voor melanoom: niet therapeutisch, maar stagerend [Sentinel lymph node procedure in melanoma patients: a staging procedure, not a therapy]*. Ned Tijdschr Geneesk. 2014;158:A8113. Dutch. PMID: 25370949.
197. **van Akkooi AC**, Eggermont AM. *SLNB in melanoma-DFS a true and cost-effective benefit?* Nat Rev Clin Oncol. 2014 Nov;11(11). doi: 10.1038/nrclinonc.2014.65-c3. Epub 2014 Oct 14. PMID: 25311352.
198. Voit CA, **van Akkooi AC**, Eggermont AM, Tüttenberg A. *Ultrasound diagnosis of an atypical axillary lesion*. Melanoma Res. 2014 Oct;24(5):517-21. doi: 10.1097/CMR.000000000000105. PMID: 25003535.

199. Voit CA, Gooskens SL, Siegel P, Schaefer G, Schoengen A, Röwert J, **van Akkooi AC**, Eggermont AM. *Ultrasound-guided fine needle aspiration cytology as an addendum to sentinel lymph node biopsy can perfect the staging strategy in melanoma patients*. Eur J Cancer. 2014 Sep;50(13):2280-8. doi: 10.1016/j.ejca.2014.05.027. Epub 2014 Jul 3. PMID: 24999208.
200. **van Akkooi AC**. *Sentinel node followed by completion lymph node dissection versus nodal observation: staging or therapeutic? Controversy continues despite final results of MSLT-1*. Melanoma Res. 2014 Aug;24(4):291-4. doi: 10.1097/CMR.000000000000073. PMID: 24992628.
201. Gos A, Jurkowska M, **van Akkooi A**, Robert C, Kosela-Paterczyk H, Koljenović S, Kamsukom N, Michej W, Jeziorski A, Pluta P, Verhoef C, Siedlecki JA, Eggermont AM, Rutkowski P. *Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site*. Ann Surg Oncol. 2014 Dec;21(13):4317-23. doi: 10.1245/s10434-014-3799-y. Epub 2014 May 28. PMID: 24866436; PMCID: PMC4218979.
202. Ulrich J, **van Akkooi AC**, Eggermont AM, Voit CA. *Sonografische Kriterien zur Diagnostik von Metastasen im Sentinel-Lymphknoten bei Patienten mit malignem Melanom [Sonographic criteria for diagnosing sentinel node metastases in melanoma patients]*. Ultraschall Med. 2015 Apr;36(2):149-53. German. doi: 10.1055/s-0034-1366360. Epub 2014 Apr 24. PMID: 24764213.
203. **van Akkooi AC**, Eggermont AM. *Melanoma: MSLT-1--SNB is a biomarker, not a therapeutic intervention*. Nat Rev Clin Oncol. 2014 May;11(5):248-9. doi: 10.1038/nrclinonc.2014.64. Epub 2014 Apr 8. PMID: 24710577.
204. van Lanschot CG, Koljenović S, Grunhagen DJ, Verhoef C, **van Akkooi AC**. *Pigmentation in the sentinel node correlates with increased sentinel node tumor burden in melanoma patients*. Melanoma Res. 2014 Jun;24(3):261-6. doi: 10.1097/CMR.000000000000061. PMID: 24608184.
205. van der Leest RJ, van Steenberg LN, Hollestein LM, de Vries E, Nijsten T, **van Akkooi AC**, Janssen-Heijnen ML, Coebergh JW. *Conditional survival of malignant melanoma in The Netherlands: 1994-2008*. Eur J Cancer. 2014 Feb;50(3):602-10. doi: 10.1016/j.ejca.2013.10.019. Epub 2013 Nov 18. PMID: 24262585.
206. van der Ploeg AP, **van Akkooi AC**, Haydu LE, Scolyer RA, Murali R, Verhoef C, Thompson JF, Eggermont AM. *The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients*. Eur J Cancer. 2014 Jan;50(1):111-20. doi: 10.1016/j.ejca.2013.08.023. Epub 2013 Sep 25. PMID: 24074765.
207. Brinkman JN, **van Akkooi AC**, Jaquet JB, Leeuwenburgh BP, Fioole B, Akkersdijk GP. *Hypothenar-hamersyndroom: zeldzame arteriële stoornis van de hand door stomp trauma [Hypothenar hammer syndrome; rare arterial disorder of the hand due to blunt trauma]*. Ned Tijdschr Geneesk. 2013;157(21):A6077. Dutch. PMID: 23693009.
208. **van Akkooi AC**, Nijsten T. *A costly revolution for a subgroup of patients with metastatic melanoma*. Br J Dermatol. 2013 Mar;168(3):467-70; discussion 470-1. doi: 10.1111/bjd.12238. PMID: 23445310.



209. **van Akkooi AC.** *Comments and controversies: sentinel node and lymphadenectomy in melanoma: staging or therapeutical?: what to expect from the multicenter selective lymphadenectomy trial-1 results in melanoma?* Melanoma Res. 2013 Jun;23(3):181-4. doi: 10.1097/CMR.0b013e32835f28f5. PMID: 23442345.
210. van der Ploeg AP, **van Akkooi AC**, Verhoef C, Eggermont AM. *Completion lymph node dissection after a positive sentinel node: no longer a must?* Curr Opin Oncol. 2013 Mar;25(2):152-9. doi: 10.1097/CCO.0b013e32835dafb4. PMID: 23328628.
211. Zdzienicki M, Rutkowski P, Nowecki ZI, **van Akkooi AC**, Michej W, Dziewirski W, Świtaj T, Pierkowski A, Sałamacha M, Bylina E, Eggermont AM. *The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases.* Eur J Surg Oncol. 2013 Mar;39(3):304-10. doi: 10.1016/j.ejso.2012.12.014. Epub 2013 Jan 5. PMID: 23298828.
212. van der Ploeg AP, **van Akkooi AC**, Rutkowski P, Cook M, Nieweg OE, Rossi CR, Testori A, Suci S, Verhoef C, Eggermont AM; *European Organization for Research and Treatment of Cancer Melanoma Group.* *Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection.* Br J Surg. 2012 Oct;99(10):1396-405. doi: 10.1002/bjs.8878. PMID: 22961519.
213. **van Akkooi AC**, Cook MG, Eggermont AM. *Increased sampling will lead to an increase in detection, but is it clinically relevant? Reply letter regarding: "Treatment influencing down-staging in EORTC Melanoma Group sentinel node histological protocol compared with complete step-sectioning: a national multicentre study" by Riber-Hansen et al.* Eur J Cancer. 2012 Oct;48(15):2488-9; author reply 2486-7. doi: 10.1016/j.ejca.2012.02.068. Epub 2012 Jun 13. PMID: 22698385.
214. Ulrich J, **van Akkooi AJ**, Eggermont AM, Voit C. *New developments in melanoma: utility of ultrasound imaging (initial staging, follow-up and pre- SLNB).* Expert Rev Anticancer Ther. 2011 Nov;11(11):1693-701. doi: 10.1586/era.11.115. PMID: 22050018.
215. Voit CA, **van Akkooi AC**, Eggermont AM, Schäfer-Hesterberg G, Kron M, Ulrich J, Sterry W, Schoengen A, Rademaker J. *Fine needle aspiration cytology of palpable and nonpalpable lymph nodes to detect metastatic melanoma.* J Natl Cancer Inst. 2011 Dec 7;103(23):1771-7. doi: 10.1093/jnci/djr381. Epub 2011 Sep 21. PMID: 21940673.
216. Voit CA, **van Akkooi AJ**, Schäfer-Hesterberg G, Sterry W, Eggermont AM. *Multimodality approach to the sentinel node: an algorithm for the use of presentinel lymph node biopsy ultrasound (after lymphoscintigraphy) in conjunction with presentinel lymph node biopsy fine needle aspiration cytology.* Melanoma Res. 2011 Oct;21(5):450-6. doi: 10.1097/CMR.0b013e3283485f27. PMID: 21673603.
217. Prens SP, van der Ploeg AP, **van Akkooi AC**, van Montfort CA, van Geel AN, de Wilt JH, Eggermont AM, Verhoef C. *Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site.* Ann Surg Oncol. 2011 Dec;18(13):3586-92. doi: 10.1245/s10434-011-1801-5. Epub 2011 May 25. PMID: 21611857; PMCID: PMC3222814.



218. van der Ploeg AP, **van Akkooi AC**, Schmitz PI, van Geel AN, de Wilt JH, Eggermont AM, Verhoef C. *Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection*. Ann Surg Oncol. 2011 Nov;18(12):3300-8. doi: 10.1245/s10434-011-1741-0. Epub 2011 May 3. PMID: 21537867; PMCID: PMC3192282.
219. van der Ploeg AP, **van Akkooi AC**, Rutkowski P, Nowecki ZI, Michej W, Mitra A, Newton-Bishop JA, Cook M, van der Ploeg IM, Nieweg OE, van den Hout MF, van Leeuwen PA, Voit CA, Cataldo F, Testori A, Robert C, Hoekstra HJ, Verhoef C, Spatz A, Eggermont AM. *Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria*. J Clin Oncol. 2011 Jun 1;29(16):2206-14. doi: 10.1200/JCO.2010.31.6760. Epub 2011 Apr 25. PMID: 21519012.
220. Schaefer-Hesterberg G, **Akkooi AJ**, Letsch A, Roewert J, Blume-Peytavi U, Keilholz U, Voit C. *Clinically misinterpreted melanoma metastases can correctly be diagnosed by ultrasound-guided fine needle aspiration cytology*. Eur J Dermatol. 2011 Mar-Apr;21(2):238-41. doi: 10.1684/ejd.2011.1275. PMID: 21489911.
221. Voit CA, **van Akkooi AC**, Catalano O. *Recent article by T. Rettenbacher describing the use of ultrasound (US) for the assessment of peripheral lymph nodes (Rettenbacher T. Ultraschall in Med 2010; 31: 344 – 362)*. Ultraschall Med. 2011 Apr;32(2):210-1. doi: 10.1055/s-0031-1273255. Epub 2011 Apr 4. PMID: 21465426.
222. Voit CA, **van Akkooi AC**, Eggermont AM. *Role of ultrasound in the assessment of the sentinel node of melanoma patients*. AJR Am J Roentgenol. 2010 Dec;195(6):W474-5; author reply W476. doi: 10.2214/AJR.10.4833. PMID: 21098184.
223. van der Ploeg AP, **van Akkooi AC**, Schmitz PI, Koljenovic S, Verhoef C, Eggermont AM. *EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria*. Eur J Cancer. 2010 Sep;46(13):2414-21. doi: 10.1016/j.ejca.2010.06.003. PMID: 20621467.
224. Voit CA, **van Akkooi AJ**, Schäfer-Hesterberg G, Sterry W, Eggermont AM. *The value of preoperative ultrasound (after lymphoscintigraphy) in conjunction with pre-sentinel lymph node biopsy fine-needle aspiration outweighs the usage of ultrasound alone in conjunction with lymphoscintigraphy: the need for an algorithm*. Melanoma Res. 2010 Aug;20(4):357-9. doi: 10.1097/CMR.0b013e32833adf13. PMID: 20613456.
225. Rutkowski P, Nowecki ZI, **van Akkooi AC**, Kulik J, Wanda M, Siedlecki JA, Eggermont AM, Ruka W. *Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden*. Ann Surg Oncol. 2010 Dec;17(12):3314-23. doi: 10.1245/s10434-010-1142-9. Epub 2010 Jul 7. PMID: 20607422; PMCID: PMC2995879.
226. **van Akkooi AC**, Verhoef C, Eggermont AM. *Importance of tumor load in the sentinel node in melanoma: clinical dilemmas*. Nat Rev Clin Oncol. 2010 Aug;7(8):446-54. doi: 10.1038/nrclinonc.2010.100. Epub 2010 Jun 22. PMID: 20567244.
227. Koomen ER, de Vries E, van Kempen LC, **van Akkooi AC**, Guchelaar HJ, Louwman MW, Nijsten T, Coebergh JW. *Epidemiology of extracutaneous melanoma in the Netherlands*. Cancer

Epidemiol Biomarkers Prev. 2010 Jun;19(6):1453-9. doi: 10.1158/1055-9965.EPI-09-1267. Epub 2010 May 25. PMID: 20501769.

228. **van Akkooi AC**, Dokter J, Boxma H. *Unusual first presentation of metastatic pancreatic cancer as skin metastases in a burn patient*. Burns. 2010 Sep;36(6):e111-4. doi: 10.1016/j.burns.2009.12.004. Epub 2010 Apr 13. PMID: 20392566.
229. **van Akkooi AC**, Voit CA, Verhoef C, Eggermont AM. *New developments in sentinel node staging in melanoma: controversies and alternatives*. Curr Opin Oncol. 2010 May;22(3):169-77. doi: 10.1097/CCO.0b013e328337aa78. PMID: 20168231.
230. Voit C, **van Akkooi AC**, Schäfer-Hesterberg G, Schoengen A, Kowalczyk K, Roewert JC, Sterry W, Eggermont AM. *Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma*. J Clin Oncol. 2010 Feb 10;28(5):847-52. doi: 10.1200/JCO.2009.25.7428. Epub 2010 Jan 11. PMID: 20065175.
231. Rutkowski P, Zdzienicki M, Nowecki ZI, **van Akkooi AC**. *Surgery of primary melanomas*. Cancers (Basel). 2010 May 11;2(2):824-41. doi: 10.3390/cancers2020824. PMID: 24281096; PMCID: PMC3835107.
232. **van Akkooi AC**, Voit CA, Verhoef C, Eggermont AM. *Potential cost- effectiveness of US-guided FNAC in melanoma patients as a primary procedure and in follow-up*. Ann Surg Oncol. 2010 Feb;17(2):660-2; author reply 663-4. doi: 10.1245/s10434-009-0807-8. PMID: 19921338; PMCID: PMC2816814.
233. **van Akkooi AC**, Spatz A, Eggermont AM, Mihm M, Cook MG. *Expert opinion in melanoma: the sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden*. Eur J Cancer. 2009 Nov;45(16):2736-42. doi: 10.1016/j.ejca.2009.08.015. Epub 2009 Sep 18. PMID: 19767199.
234. Voit CA, **van Akkooi AC**, Schäfer-Hesterberg G, Schoengen A, Schmitz PI, Sterry W, Eggermont AM. *Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma?* J Clin Oncol. 2009 Oct 20;27(30):4994-5000. doi: 10.1200/JCO.2008.19.0033. Epub 2009 Sep 8. PMID: 19738131.
235. **van Akkooi AC**, Nowecki ZI, Voit C, Schäfer-Hesterberg G, Michej W, de Wilt JH, Rutkowski P, Verhoef C, Eggermont AM. *Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes*. Ann Surg. 2008 Dec;248(6):949-55. doi: 10.1097/SLA.0b013e31818fefe0. PMID: 19092339.
236. **van Akkooi AC**, de Wilt JH, Verhoef C, Eggermont AM. *The Rotterdam criteria for sentinel node tumor load: the simplest prognostic factor?* J Clin Oncol. 2008 Dec 20;26(36):6011; author reply 6012. doi: 10.1200/JCO.2008.19.5420. Epub 2008 Nov 17. PMID: 19018076.
237. Voit CA, Schäfer-Hesterberg G, Kron M, **van Akkooi AC**, Rademaker J, Lukowsky A, Schoengen A, Schwürzer-Voit M, Sterry W, Krause M, Rößert-Huber J, Eggermont AM. *Impact of molecular staging methods in primary melanoma: reverse-transcriptase polymerase chain reaction (RT-PCR)*

- of ultrasound-guided aspirate of the sentinel node does not improve diagnostic accuracy, but RT-PCR of peripheral blood does predict survival.* J Clin Oncol. 2008 Dec 10;26(35):5742-7. doi: 10.1200/JCO.2007.13.7653. Epub 2008 Nov 3. PMID: 18981467.
238. de Wilt JH, **van Akkooi AC**, Verhoef C, Eggermont AM. *Detection of melanoma micrometastases in sentinel nodes - the cons.* Surg Oncol. 2008 Sep;17(3):175-81. doi: 10.1016/j.suronc.2008.06.004. Epub 2008 Jul 9. PMID: 18617395.
239. **van Akkooi AC**, de Wilt JH, Voit C, Verhoef C, Suci S, Eggermont AM. *Sentinel lymph-node false positivity in melanoma.* Nat Clin Pract Oncol. 2008 Apr;5(4):E2. doi: 10.1038/ncponc1111. PMID: 18376421.
240. **van Akkooi AC**, de Wilt JH, Verhoef C, Eggermont AM. *Cutaneous melanoma and sentinel lymph node biopsy.* Ann Surg Oncol. 2008 Jun;15(6):1808-9; author reply 1810-1. doi: 10.1245/s10434-008-9824-2. Epub 2008 Feb 2. PMID: 18246398; PMCID: PMC2373859.
241. **van Akkooi AC**, de Wilt JH, Verhoef C, Eggermont AM. *Isolated tumor cells and long-term prognosis of patients with melanoma.* Ann Surg Oncol. 2008 May;15(5):1547-8. doi: 10.1245/s10434-007-9767-z. Epub 2008 Jan 15. PMID: 18197454; PMCID: PMC2277443.
242. **van Akkooi AC**, Bouwhuis MG, de Wilt JH, Kliffen M, Schmitz PI, Eggermont AM. *Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma.* Br J Surg. 2007 Oct;94(10):1293-9. doi: 10.1002/bjs.5814. PMID: 17702089.
243. **van Akkooi AC**, Bouwhuis MG, van Geel AN, Hoedemaker R, Verhoef C, Grunhagen DJ, Schmitz PI, Eggermont AM, de Wilt JH. *Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.* Eur J Surg Oncol. 2007 Feb;33(1):102-8. doi: 10.1016/j.ejso.2006.10.032. Epub 2006 Dec 11. PMID: 17161577.
244. **van Akkooi AC**, de Wilt JH, Verhoef C, Schmitz PI, van Geel AN, Eggermont AM, Kliffen M. *Clinical relevance of melanoma micrometastases (<math>\leq 0.1\text{ mm}</math>) in sentinel nodes: are these nodes to be considered negative?* Ann Oncol. 2006 Oct;17(10):1578-85. doi: 10.1093/annonc/mdl176. Epub 2006 Sep 12. PMID: 16968875.
245. **van Akkooi AC**, van Geel AN, Bessems JH, den Bakker MA. *Extra-axial chordoma.* J Bone Joint Surg Br. 2006 Sep;88(9):1232-4. doi: 10.1302/0301-620X.88B9.17873. PMID: 16943479.
246. **van Akkooi AC**, Golab-Schwarz HD, Eggermont AM, van Geel AN. *Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's witness.* Eur J Cardiothorac Surg. 2006 Aug;30(2):408-10. doi: 10.1016/j.ejcts.2006.04.020. Epub 2006 Jul 7. PMID: 16829108.
247. **van Akkooi AC**, Verhoef C, van Geel AN, Kliffen M, Eggermont AM, de Wilt JH. *Sentinel node biopsy for clear cell sarcoma.* Eur J Surg Oncol. 2006 Nov;32(9):996-9. doi: 10.1016/j.ejso.2006.03.044. Epub 2006 May 2. PMID: 16672185.
248. **van Akkooi AC**, de Wilt JH, Verhoef C, Graveland WJ, van Geel AN, Kliffen M, Eggermont AM. *High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma.* Eur J Cancer. 2006 Feb;42(3):372-80. doi: 10.1016/j.ejca.2005.10.023. Epub 2006 Jan 5. PMID: 16403622.

249. **van Akkooi AC**, de Wilt JH, van Geel AN, Verhoef C, Eggermont AM. *Schildwachtklierbiopsie bij het melanoom: prognostische betekenis en nadelen bij 300 patiënten [Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients]*. Ned Tijdschr Geneeskd. 2005 Nov 5;149(45):2538; author reply 2538-9. Dutch. PMID: 16304897.

#### Other Peer Reviewed Publications

1. **van Akkooi ACJ**, Mandala M, Nathan P, Haydon A, Postow M, Rutkowski P. Adjuvant systemic therapy in melanoma: Relative versus absolute benefit; the number needed to treat (NNT) versus number needed to harm (NNH)? EJC Skin Cancer. 2024 Feb;2:100021. doi: 10.1016/ejcskn.2024.100021
2. **van Akkooi A**, Astratinei V, van Elst K, Steuten L. *Adjuvant immune checkpoint blockade revisited; the need to consider more factors and involve all stakeholders*. EJC Skin Cancer. 2023 Dec;2:100014. doi:10.1016/ejcskn.2023.100014
3. Madu MF, van Veenendaal LM, van de Wiel B, Tesselaar MET, **van Akkooi AJC**. *Concurrent Merkel Cell Carcinoma and Melanoma in Individual Patients Presents a Treatment Challenge: A Case Series*. Clinical Skin Cancer 2017;2(1):69-72. doi:10.1016/j.clsc.2017.08.002
4. Henneman R, Wouters MWJM, **van Akkooi ACJ**, ter Meulen S, Balm AJM, van der Hage JA. *Prevention of Seroma After Inguinal Lymph Node Dissection by TachoSil Application: A Pilot Study*. Clinical Skin Cancer 2017;2(1)5-9. doi:10.1016/j.clsc.2017.08.005
5. **van Akkooi ACJ**. *News From the Society of Surgical Oncology (SSO) Annual Cancer Symposium (March 15-18, 2017, Seattle, WA): A New Hope – Neoadjuvant BRAF/MEK Inhibition for BRAF-Mutated Stage III Melanoma*. Clinical Skin Cancer. 2016;1(2):57-8. doi:10.1016/j.clsc.2017.04.003
6. Madu MF, Rozeman EAL, van der Hage JA, Wouters MWJM, Klop WMC, van Thienen JVH, Blank CU, Haanen JBAG, **van Akkooi ACJ**. *Neoadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib to Allow Complete Surgical Resection in Patients With BRAF Mutated, Prior Unresectable Stage III or IV Melanoma) Trial*. Clinical Skin Cancer. 2016;1(1):48-52. doi:10.1016/j.clsc.2016.11.006